Claims:

1. A method of treating a mammal in need thereof, wherein the mammal would receive symptomatic relief by decreasing the level of TNF-α comprising administering an alpha 7 nAChR full agonist.

2. The method of claim 1, wherein the symptomatic relief would be to treat the mammal for infection, inflammation, cancer, or diabetes.

3. The method of claim 2, wherein the mammal would optionally receive an antiviral or antibacterial agent for a therapeutically effective interval, and wherein infection or inflammation is caused by rheumatoid arthritis; rheumatoid spondylitis; muscle degeneration; osteoporosis; osteoarthritis; psoriasis; contact dermatitis; bone resorption diseases; atherosclerosis; Paget's disease; uveititis; gouty arthritis; inflammatory bowel disease; adult respiratory distress syndrome; Crohn's disease; rhinitis; ulcerative colitis; anaphylaxis; asthma; Reiter's syndrome; tissue rejection of a graft; ischemia reperfusion injury; brain trauma; stroke; multiple sclerosis; cerebral malaria; sepsis; septic shock; toxic shock syndrome; fever and myalgias due to infection; HIV-1, HIV-2, HIV-3; cytomegalovirus; influenza; adenovirus; a herpes virus; or herpes zoster.

4. The method of claim 2, wherein cancer is multiple myeloma; acute and chronic myelogenous leukemia; or cancer-associated cachexia, and where the mammal would optionally receive at least one of an anticancer agent or antiemetic agent for a therapeutically effective interval.

5. The method of claim 2, wherein diabetes is type I and type II diabetes, and wherein the mammal optionally receives at least one agent for the treatment of diabetes for a therapeutically effective interval.

6. The method of claim 2, wherein diabetes is associated with pancreatic beta cell destruction.

7. The method of claim 1, wherein the full agonist is a compound of formula I:

Azabicyclo-N(R_1)-C(=X)-W

Formula I

wherein Azabicyclo is





X is O, or S;

R_0 is H, lower alkyl, substituted lower alkyl, or lower haloalkyl;

Each R_1 is H, alkyl, cycloalkyl, haloalkyl, substituted phenyl, or substituted naphthyl;

Each R_2 is independently F, Cl, Br, I, alkyl, substituted alkyl, haloalkyl, cycloalkyl, aryl, or R_2 is absent;

R_{2-3} is H, F, Cl, Br, I, alkyl, haloalkyl, substituted alkyl, cycloalkyl, or aryl;

Each R_3 is independently H, alkyl, or substituted alkyl;

R_4 is H, alkyl, an amino protecting group, or an alkyl group having 1-3 substituents selected from F, Cl, Br, I, -OH, -CN, $-NH_2$, -NH(alkyl), or $-N(alkyl)_2$;

R_5 is 5-membered heteroaromatic mono-cyclic moieties containing within the ring 1-3 heteroatoms independently selected from the group consisting of -O-, =N-, $-N(R_{10})-$, and -S-, and having 0-1 substituent selected from R_9 and further having 0-3 substituents independently selected from F, Cl, Br, or I, or R_5 is 9-membered fused-ring moieties having a 6-membered ring fused to a 5-membered ring and having the formula



wherein L_1 is O, S, or NR_{10},



wherein L is CR_{12} or N, L_2 and L_3 are independently selected from CR_{12}, $C(R_{12})_2$, O, S, N, or NR_{10}, provided that both L_2 and L_3 are not simultaneously O, simultaneously S, or simultaneously O and S, or



wherein L is CR_{12} or N, and L_2 and L_3 are independently selected from CR_{12}, O, S, N, or NR_{10}, and each 9-membered fused-ring moiety having 0-1 substituent selected from R_9 and further having 0-3 substituent(s) independently selected from F, Cl, Br, or I, wherein the R_5 moiety attaches to other substituents as defined in formula I at any position as valency allows;

R_6 is 6-membered heteroaromatic mono-cyclic moieties containing within the ring 1-3 heteroatoms selected from =N- and having 0-1 substituent selected from R_9 and 0-3 substituent(s) independently selected from F, Cl, Br, or I, or R_6 is 10-membered heteroaromatic bi-cyclic moieties containing within one or both rings 1-3 heteroatoms selected from =N-, including, but not limited to, quinolinyl or isoquinolinyl, each 10-membered fused-ring moiety having 0-1 substituent selected from R_9 and 0-3 substituent(s) independently selected from F, Cl, Br, or I, wherein the R_6 moiety attaches to other substituents as defined in formula I at any position as valency allows;

R_7 is alkyl, substituted alkyl, haloalkyl, $-OR_{11}$, -CN, $-NO_2$, $-N(R_8)_2$;

Each R_8 is independently H, alkyl, cycloalkyl, heterocycloalkyl, alkyl substituted with 1 substituent selected from R_{13}, cycloalkyl substituted with 1 substituent selected from R_{13}, heterocycloalkyl substituted with 1 substituent selected from R_{13}, haloalkyl, halocycloalkyl, haloheterocycloalkyl, phenyl, or substituted phenyl;

R_9 is alkyl, cycloalkyl, heterocycloalkyl, haloalkyl, halocycloalkyl, haloheterocycloalkyl, $-OR_{14}$, $-SR_{14}$, $-N(R_{14})_2$, $-C(O)R_{14}$, $-C(O)N(R_{14})_2$, -CN, $-NR_{14}C(O)R_{14}$, $-S(O)_2N(R_{14})_2$, $-NR_{14}S(O)_2R_{14}$, $-NO_2$, alkyl substituted with 1-4 substituent(s) independently selected from F, Cl, Br, I, or R_{13}, cycloalkyl substituted with 1-4 substituent(s) independently selected from F, Cl, Br, I, or R_{13}, or

heterocycloalkyl substituted with 1-4 substituent(s) independently selected from F, Cl, Br, I, or R_{13};

R_{10} is H, alkyl, haloalkyl, substituted alkyl, cycloalkyl, halocycloalkyl, substituted cycloalkyl, phenyl, or phenyl having 1 substituent selected from R_7 and further having 0-3 substituents independently selected from F, Cl, Br, or I;

Each R_{11} is independently H, alkyl, cycloalkyl, heterocycloalkyl, haloalkyl, halocycloalkyl, or haloheterocycloalkyl;

Each R_{12} is independently H, F, Cl, Br, I, alkyl, cycloalkyl, heterocycloalkyl, haloalkyl, halocycloalkyl, haloheterocycloalkyl, substituted alkyl, substituted cycloalkyl, substituted heterocycloalkyl, -CN, $-NO_2$, $-OR_{14}$, $-SR_{14}$, $-N(R_{14})_2$, $-C(O)R_{14}$, $-C(O)N(R_{14})_2$, $-NR_{14}C(O)R_{14}$, $-S(O)_2N(R_{14})_2$, $-NR_{14}S(O)_2R_{14}$, or a bond;

R_{13} is $-OR_{14}$, $-SR_{14}$, $-N(R_{14})_2$, $-C(O)R_{14}$, $-C(O)N(R_{14})_2$, -CN, $-CF_3$, $-NR_{14}C(O)R_{14}$, $-S(O)_2N(R_{14})_2$, $-NR_{14}S(O)_2R_{14}$, or $-NO_2$;

Each R_{14} is independently H, alkyl, cycloalkyl, heterocycloalkyl, haloalkyl, halocycloalkyl, or haloheterocycloalkyl;

wherein W is (A):

(A-1)

or



(A-2)

wherein R_{A-1a} is H, alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, haloalkyl, haloalkenyl, haloalkynyl, halocycloalkyl, haloheterocycloalkyl, substituted alkyl, substituted alkenyl, substituted alkynyl, substituted cycloalkyl, substituted heterocycloalkyl, aryl, $-R_5$, R_6, $-OR_{A-3}$, $-SR_{A-3}$, F, Cl, Br, I, $-N(R_{A-3})_2$, $-C(O)R_{A-3}$, -CN, $-C(O)N(R_{A-3})_2$, $-NR_{A-3}C(O)R_{A-3}$, $-S(O)R_{A-3}$, $-OS(O)_2R_{A-3}$, $-NR_{A-3}S(O)_2R_{A-3}$, $-NO_2$, and $-N(H)C(O)N(H)R_{A-3}$;

R_{A-1b} is $-O-R_{A-3}$, $-S-R_{A-3}$, $-S(O)-R_{A-3}$, $-C(O)-R_{A-7}$, and alkyl substituted on the ω carbon with R_{A-7};

Each R_{A-3} is independently selected from H, alkyl, haloalkyl, substituted alkyl, cycloalkyl, halocycloalkyl, substituted cycloalkyl, heterocycloalkyl, halo-heterocycloalkyl, substituted heterocycloalkyl, R_5, R_6, phenyl, or substituted phenyl;

R_{A-4} is selected from cycloalkyl, halocycloalkyl, substituted cycloalkyl, heterocycloalkyl, haloheterocycloalkyl, or substituted heterocycloalkyl;

Each R_{A-5} is independently selected from cycloalkyl, halocycloalkyl, substituted cycloalkyl, heterocycloalkyl, haloheterocycloalkyl, substituted heterocycloalkyl, R_5, R_6, phenyl, or substituted phenyl;

Each R_{A-6} is independently selected from alkyl, haloalkyl, substituted alkyl, cycloalkyl, halocycloalkyl, substituted cycloalkyl, heterocycloalkyl, haloheterocycloalkyl, substituted heterocycloalkyl, R_5, R_6, phenyl, or substituted phenyl;

R_{A-7} is selected from aryl, R_5, or R_6;

wherein W is (B):



wherein B^0 is -O-, -S-, or -N(R_{B-0})-;

B^1 and B^2 are independently selected from =N-, or =C(R_{B-1})-;

B^3 is =N-, or =CH-, provided that when both B^1 and B^2 are =C(R_{B-1})- and B^3 is =CH-, only one =C(R_{B-1})- can be =CH-, and further provided that when B^0 is -O-, B^2 is =C(R_{B-1})- and B^3 is =C(H)-, B^1 cannot be =N-,

R_{B-0} is H, alkyl, cycloalkyl, heterocycloalkyl, haloalkyl, halocycloalkyl, haloheterocycloalkyl, substituted alkyl, substituted cycloalkyl, substituted heterocycloalkyl, or aryl, and provided that when B is (B-2) and B^3 is =N- and B^0 is N(R_{B-0}), R_{B-0} cannot be phenyl or substituted phenyl;

R_{B-1} is H, alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, haloalkyl, haloalkenyl, haloalkynyl, halocycloalkyl, haloheterocycloalkyl, substituted alkyl, substituted alkenyl, substituted alkynyl, substituted cycloalkyl, substituted heterocycloalkyl, aryl, -OR_{B-2}, -SR_{B-2}, F, Cl, Br, I, -N(R_{B-2})$_2$, -C(O)R_{B-2}, -C(O)N(R_{B-2})$_2$, -CN, -NR_{B-2}C(O)R_{B-4}, -S(O)$_2$N(R_{B-2})$_2$, -OS(O)$_2$$R_{B-4}$, -S(O)$_2$$R_{B-2}$, -N$R_{B-2}$S(O)$_2$$R_{B-2}$, -N(H)C(O)N(H)$R_{B-2}$, -$NO_2$, R_5, and R_6;

Each R_{B-2} is independently H, alkyl, haloalkyl, substituted alkyl, cycloalkyl, halocycloalkyl, substituted cycloalkyl, heterocycloalkyl, haloheterocycloalkyl, substituted heterocycloalkyl, R_5, R_6, phenyl, or substituted phenyl;

Each R_{B-3} is independently H, alkyl, haloalkyl, limited substituted alkyl, cycloalkyl, halocycloalkyl, substituted cycloalkyl, heterocycloalkyl, haloheterocycloalkyl, substituted heterocycloalkyl;

R_{B-4} is independently H, alkyl, cycloalkyl, heterocycloalkyl, haloalkyl, halocycloalkyl, or haloheterocycloalkyl;

wherein W is (C):

(C) is a six-membered heterocyclic ring system having 1-2 nitrogen atoms or a 10-membered bicyclic-six-six-fused-ring system having up to two nitrogen atoms within either or both rings, provided that no nitrogen is at a bridge of the bicyclic-six-six-fused-ring system, and further having 1-2 substitutents independently selected from R_{C-1};

Each R_{C-1} is independently H, F, Cl, Br, I, alkyl, haloalkyl, substituted alkyl, alkenyl, haloalkenyl, substituted alkenyl, alkynyl, haloalkynyl, substituted alkynyl, cycloalkyl, halocycloalkyl, substituted cycloalkyl, heterocycloalkyl, haloheterocycloalkyl, substituted heterocycloalkyl, lactam heterocycloalkyl, phenyl, substituted phenyl, $-NO_2$, -CN, $-OR_{C-2}$, $-SR_{C-2}$, $-SOR_{C-2}$, $-SO_2R_{C-2}$, $-NR_{C-2}C(O)R_{C-2}$, $-N(R_{C-2})_2$, $-C(O)R_{C-2}$, $-C(O)_2R_{C-2}$, $-C(O)N(R_{C-2})_2$, -SCN, $-S(O)N(R_{C-2})_2$, $-S(O)_2N(R_{C-2})_2$, $-NR_{C-2}S(O)_2R_{C-2}$, R_5, or R_6;

Each R_{C-2} is independently H, alkyl, cycloalkyl, heterocycloalkyl, alkyl substituted with 1 substituent selected from R_{C-5}, cycloalkyl substituted with 1 substituent selected from R_{C-5}, heterocycloalkyl substituted with 1 substituent selected from R_{C-5}, haloalkyl, halocycloalkyl, haloheterocycloalkyl, phenyl, or substituted phenyl;

Each R_{C-3} is independently H, alkyl, or substituted alkyl;

R_{C-4} is H, alkyl, an amino protecting group, or an alkyl group having 1-3 substituents selected from F, Cl, Br, I, -OH, -CN, $-NH_2$, -NH(alkyl), or $-N(alkyl)_2$;

R_{C-5} is -CN, $-CF_3$, $-NO_2$, $-OR_{C-6}$, $-SR_{C-6}$, $-N(R_{C-6})_2$, $-C(O)R_{C-6}$, $-SOR_{C-6}$, $-SO_2R_{C-6}$, $-C(O)N(R_{C-6})_2$, $-NR_{C-6}C(O)R_{C-6}$, $-S(O)_2N(R_{C-6})_2$, or $-NR_{C-6}S(O)_2R_{C-6}$;

Each R_{C-6} is independently H, alkyl, cycloalkyl, heterocycloalkyl, haloalkyl, halocycloalkyl, or haloheterocycloalkyl;

wherein W is (D):



provided that the bond between the -C(=X)- group and the W group may be attached at any available carbon atom within the D group as provided in R_{D-1}, R_{D-3}, and R_{D-4};

D^0, D^1, D^2, and D^3 are N or $C(R_{D-1})$ provided that up to one of D^0, D^1, D^2, or D^3 is N and the others are $C(R_{D-1})$, further provided that when the core molecule is attached at D^2 and D^0 or D^1 is N, D^3 is C(H), and further provided that there is only one attachment to the core molecule;

D^4---D^5---D^6 is selected from $N(R_{D-2})$-$C(R_{D-3})$=$C(R_{D-3})$, N=$C(R_{D-3})$-$C(R_{D-4})_2$, $C(R_{D-3})$=$C(R_{D-3})$-$N(R_{D-2})$, $C(R_{D-3})_2$-$N(R_{D-2})$-$C(R_{D-3})_2$, $C(R_{D-4})_2$-$C(R_{D-3})$=N, $N(R_{D-2})$-$C(R_{D-3})_2$-$C(R_{D-3})_2$, $C(R_{D-3})_2$-$C(R_{D-3})_2$-$N(R_{D-2})$, O-$C(R_{D-3})$=$C(R_{D-3})$, O-$C(R_{D-3})_2$-$C(R_{D-3})_2$, $C(R_{D-3})_2$-O-$C(R_{D-3})_2$, $C(R_{D-3})$=$C(R_{D-3})$-O, $C(R_{D-3})_2$-$C(R_{D-3})_2$-O, S-$C(R_{D-3})$=$C(R_{D-3})$, S-$C(R_{D-3})_2$-$C(R_{D-3})_2$, $C(R_{D-3})_2$-S-$C(R_{D-3})_2$, $C(R_{D-3})$=$C(R_{D-3})$-S, or $C(R_{D-3})_2$-$C(R_{D-3})_2$-S;

provided that when C(X) is attached to W at D^2 and D^6 is O, $N(R_{D-2})$, or S, D^4---D^5 is not CH=CH;

and further provided that when C(X) is attached to W at D^2 and D^4 is O, $N(R_{D-2})$, or S, D^5---D^6 is not CH=CH;

Each R_{D-1} is independently H, F, Br, I, Cl, -CN, $-CF_3$, $-OR_{D-5}$, $-SR_{D-5}$, $-N(R_{D-5})_2$, or a bond to -C(X)- provided that only one of R_{D-1}, R_{D-3}, and R_{D-4} is said bond;

Each R_{D-2} is independently H, alkyl, haloalkyl, substituted alkyl, cycloalkyl, halocycloalkyl, substituted cycloalkyl, heterocycloalkyl, haloheterocycloalkyl, substituted heterocycloalkyl, R_5, or R_6;

Each R_{D-3} is independently H, F, Br, Cl, I, alkyl, substituted alkyl, haloalkyl, alkenyl, substituted alkenyl, haloalkenyl, alkynyl, substituted alkynyl, haloalkynyl, heterocycloalkyl, substituted heterocycloalkyl, lactam heterocycloalkyl, -CN, $-NO_2$, $-OR_{D-10}$, $-C(O)N(R_{D-11})_2$, $-NR_{D-10}COR_{D-12}$, $-N(R_{D-10})_2$, $-SR_{D-10}$, $-S(O)_2R_{D-10}$, $-C(O)R_{D-12}$, $-CO_2R_{D-10}$, aryl, R_5, R_6, or a bond to -C(X)- provided that only one of R_{D-1}, R_{D-3}, and R_{D-4} is said bond;

Each R_{D-4} is independently H, F, Br, Cl, I, alkyl, substituted alkyl, haloalkyl, alkenyl, substituted alkenyl, haloalkenyl, alkynyl, substituted alkynyl, haloalkynyl, heterocycloalkyl, substituted heterocycloalkyl, lactam heterocycloalkyl, -CN, $-NO_2$, $-OR_{D-10}$, $-C(O)N(R_{D-11})_2$, $-NR_{D-10}COR_{D-12}$, $-N(R_{D-11})_2$, $-SR_{D-10}$, $-CO_2R_{D-10}$, aryl, R_5, R_6, or a bond to -C(X)- provided that only one of R_{D-1}, R_{D-3}, and R_{D-4} is said bond;

Each R_{D-5} is independently H, C_{1-3} alkyl, or C_{2-4} alkenyl;

D^7 is O, S, or $N(R_{D-2})$;

D^8 and D^9 are $C(R_{D-1})$, provided that when the molecule is attached to the phenyl moiety at D^9, D^8 is CH;

Each R_{D-10} is H, alkyl, cycloalkyl, haloalkyl, substituted phenyl, or substituted naphthyl;

Each R_{D-11} is independently H, alkyl, cycloalkyl, heterocycloalkyl, alkyl substituted with 1 substituent selected from R_{13}, cycloalkyl substituted with 1 substituent selected from R_{13}, heterocycloalkyl substituted with 1 substituent selected from R_{13}, haloalkyl, halocycloalkyl, haloheterocycloalkyl, phenyl, or substituted phenyl;

R_{D-12} is H, alkyl, substituted alkyl, cycloalkyl, haloalkyl, heterocycloalkyl, substituted heterocycloalkyl, substituted phenyl, or substituted naphthyl;

wherein W is (E):



E^0 is CH or N;

R_{E-0} is H, F, Cl, Br, I, alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, haloalkyl, haloalkenyl, haloalkynyl, halocycloalkyl, haloheterocycloalkyl, substituted alkyl, substituted alkenyl, substituted alkynyl, substituted cycloalkyl, substituted heterocycloalkyl, aryl, R_5, R_6, $-OR_{E-3}$, $-SR_{E-3}$, $-N(R_{E-3})_2$, $-C(O)R_{E-3}$, -CN, $-C(O)N(R_{E-3})_2$, $-NR_{E-3}C(O)R_{E-3}$, $-S(O)R_{E-3}$, $-S(O)R_{E-5}$, $-OS(O)_2R_{E-3}$, $-NR_{E-3}S(O)_2R_{E-3}$, $-NO_2$, or $-N(H)C(O)N(H)R_{E-3}$;

E^1 is O, CR_{E-1-1}, or $C(R_{E-1-1})_2$, provided that when E^1 is CR_{E-1-1}, one R_{E-1} is a bond to CR_{E-1-1}, and further provided that at least one of E^1 or E^2 is O;

Each R_{E-1-1} is independently H, F, Br, Cl, CN, alkyl, haloalkyl, substituted alkyl, alkynyl, cycloalkyl, $-OR_E$, or $-N(R_E)_2$, provided that at least one R_{E-1-1} is H when E^1 is $C(R_{E-1-1})_2$;

Each R_{E-1} is independently H, alkyl, substituted alkyl, haloalkyl, cycloalkyl, heterocycloalkyl, or a bond to E^1 provided that E^1 is CR_{E-1-1};

E^2 is O, CR_{E-2-2}, or $C(R_{E-2-2})_2$, provided that when E^2 is CR_{E-2-2}, one R_{E-2} is a bond to CR_{E-2-2}, and further provided that at least one of E^1 or E^2 is O;

Each R_{E-2-2} is independently H, F, Br, Cl, CN, alkyl, haloalkyl, substituted alkyl, alkynyl, cycloalkyl, $-OR_E$, or $-N(R_E)_2$, provided that at least one R_{E-2-2} is H when E^2 is $C(R_{E-2-2})_2$;

Each R_{E-2} is independently H, alkyl, substituted alkyl, haloalkyl, cycloalkyl, heterocycloalkyl, or a bond to E^2 provided that E^2 is CR_{E-2-2};

Each R_E is independently H, alkyl, cycloalkyl, heterocycloalkyl, haloalkyl, halocycloalkyl, or haloheterocycloalkyl;

Each R_{E-3} is independently H, alkyl, haloalkyl, substituted alkyl, cycloalkyl, halocycloalkyl, substituted cycloalkyl, heterocycloalkyl, haloheterocycloalkyl, substituted heterocycloalkyl, R_5, R_6, phenyl, or phenyl having 1 substituent selected from R_9 and further having 0-3 substituents independently selected from F, Cl, Br, or I or substituted phenyl;

R_{E-4} is H, haloalkyl, substituted alkyl, cycloalkyl, halocycloalkyl, substituted cycloalkyl, heterocycloalkyl, haloheterocycloalkyl, substituted heterocycloalkyl, R_5, R_6, phenyl, or substituted phenyl;

Each R_{E-5} is independently H, haloalkyl, substituted alkyl, cycloalkyl, halocycloalkyl, substituted cycloalkyl, heterocycloalkyl, haloheterocycloalkyl, substituted heterocycloalkyl, R_5, or R_6;

Each R_{E-6} is independently alkyl, haloalkyl, substituted alkyl, cycloalkyl, halocycloalkyl, substituted cycloalkyl, heterocycloalkyl, haloheterocycloalkyl, substituted heterocycloalkyl, R_5, R_6, phenyl, or phenyl having 1 substituent selected from R_9 and further having 0-3 substituents independently selected from F, Cl, Br, or I;

wherein W is (F):



(F-1) (F-2)

F^0 is C(H) wherein F^1---F^2---F^3 is selected from O-C(R_{F-2})=N, O-C(R_{F-3})(R_{F-2})-N(R_{F-4}), O-C(R_{F-3})(R_{F-2})-S, O-N=C(R_{F-3}), O-C(R_{F-2})(R_{F-3})-O, S-C(R_{F-2})=N, S-C(R_{F-3})(R_{F-2})-N(R_{F-4}), S-N=C(R_{F-3}), N=C(R_{F-2})-O, N=C(R_{F-2})-S, N=C(R_{F-2})-N(R_{F-4}), N(R_{F-4})-N=C(R_{F-3}), N(R_{F-4})-C(R_{F-3})(R_{F-2})-O, N(R_{F-4})-C(R_{F-3})(R_{F-2})-S, N(R_{F-4})-C(R_{F-3})(R_{F-2})-N(R_{F-4}), C(R_{F-3})$_2$-O-N(R_{F-4}), C(R_{F-3})$_2$-N(R_{F-4})-O, C(R_{F-3})$_2$-N(R_{F-4})-S, C(R_{F-3})=N-O, C(R_{F-3})=N-S, C(R_{F-3})=N-N(R_{F-4}), or C(R_{F-3})$_2$-C(R_{F-2})(R_{F-3})-C(R_{F-3})$_2$;

F^0 is N wherein F^1---F^2---F^3 is selected from O-C(R_{F-2})=N, O-C(R_{F-3})(R_{F-2})-N(R_{F-4}), O-C(R_{F-3})(R_{F-2})-S, O-N=C(R_{F-3}) O-C(R_{F-2})(R_{F-3})-O, S-C(R_{F-2})=N, S-C(R_{F-3})(R_{F-2})-N(R_{F-4}), S-N=C(R_{F-3}), N=C(R_{F-2})-O, N=C(R_{F-2})-S, N=C(R_{F-2})-N(R_{F-4}), N(R_{F-4})-N=C(R_{F-3}), N(R_{F-4})-C(R_{F-3})(R_{F-2})-O, N(R_{F-4})-C(R_{F-3})(R_{F-2})-S, N(R_{F-4})-C(R_{F-3})(R_{F-2})-N(R_{F-4}), C(R_{F-3})$_2$-O-N(R_{F-4}), C(R_{F-3})$_2$-N(R_{F-4})-O, C(R_{F-3})$_2$-N(R_{F-4})-S, C(R_{F-3})=N-O, C(R_{F-3})=N-S, C(R_{F-3})=N-N(R_{F-4}), C(R_{F-3})=C(R_{F-2})-C(R_{F-3})$_2$, or C(R_{F-3})$_2$-C(R_{F-2})(R_{F-3})-C(R_{F-3})$_2$;

F^4 is N(R_{F-7}), O, or S;

R_{F-1} is H, F, Cl, Br, I, -CN, -CF_3, -OR_{F-8}, -SR_{F-8}, or -N(R_{F-8})$_2$;

R_{F-2} is H, F, alkyl, haloalkyl, substituted alkyl, lactam heterocycloalkyl, phenoxy, substituted phenoxy, R_5, R_6, -N(R_{F-4})-aryl, -N(R_{F-4})-substituted phenyl, -N(R_{F-4})-substituted naphthyl, -O-substituted phenyl, -O-substituted naphthyl, -S-substituted phenyl, -S-substituted naphthyl, or alkyl substituted on the ω carbon with R_{F-9};

R_{F-3} is H, F, Br, Cl, I, alkyl, substituted alkyl, haloalkyl, alkenyl, substituted alkenyl, haloalkenyl, alkynyl, substituted alkynyl, haloalkynyl, heterocycloalkyl, substituted heterocycloalkyl, lactam heterocycloalkyl, -CN, -NO_2, -OR_{F-8}, -C(O)N(R_{F-8})$_2$, -NHR_{F-8}, -NR_{F-8}COR_{F-8}, -N(R_{F-8})$_2$, -SR_{F-8}, -C(O)R_{F-8}, -CO_2R_{F-8}, aryl, R_5, or R_6;

R_{F-4} is H, or alkyl;

Each R_{F-5} is independently F, Br, Cl, I, alkyl, substituted alkyl, haloalkyl, alkenyl, substituted alkenyl, haloalkenyl, alkynyl, substituted alkynyl, haloalkynyl,

-CN, -CF_3, -OR_{F-8}, -$C(O)NH_2$, -NHR_{F-8}, -SR_{F-8}, -CO_2R_{F-8}, aryl, phenoxy, substituted phenoxy, heteroaryl, -$N(R_{F-4})$-aryl, or -O-substituted aryl;

One of R_{F-6} is H, alkyl, substituted alkyl, haloalkyl, alkenyl, substituted alkenyl, haloalkenyl, alkynyl, substituted alkynyl, haloalkynyl, -CN, F, Br, Cl, I, -OR_{F-8}, -$C(O)NH_2$, -NHR_{F-8}, -SR_{F-8}, -CO_2R_{F-8}, aryl, R_5, or R_6, and each of the other two R_{F-6} is independently selected from alkyl, substituted alkyl, haloalkyl, alkenyl, substituted alkenyl, haloalkenyl, alkynyl, substituted alkynyl, haloalkynyl, -CN, F, Br, Cl, I, -OR_{F-8}, -$C(O)NH_2$, -NHR_{F-8}, -SR_{F-8}, -CO_2R_{F-8}, aryl, R_5, or R_6;

R_{F-7} is H, alkyl, haloalkyl, substituted alkyl, cycloalkyl, halocycloalkyl, substituted cycloalkyl, phenyl, or phenyl having 1 substituent selected from R_9 and further having 0-3 substituents independently selected from F, Cl, Br, or I;

R_{F-8} is H, alkyl, substituted alkyl, cycloalkyl, haloalkyl, heterocycloalkyl, substituted heterocycloalkyl, substituted phenyl, or substituted naphthyl;

R_{F-9} is aryl, R_5, or R_6;

wherein W is (G):



G^1 is N or CH;

Each G^2 is N or $C(R_{G-1})$, provided that no more than one G^2 is N;

Each R_{G-1} is independently H, alkyl, substituted alkyl, haloalkyl, alkenyl, substituted alkenyl, haloalkenyl, alkynyl, substituted alkynyl, haloalkynyl, -CN, -NO_2, F, Br, Cl, I, -$C(O)N(R_{G-3})_2$, -$N(R_{G-3})_2$, -SR_{G-6}, -$S(O)_2R_{G-6}$, -OR_{G-6}, -$C(O)R_{G-6}$, -CO_2R_{G-6}, aryl, R_5, R_6, or two R_{G-1} on adjacent carbon atoms may combine for W to be a 6-5-6 fused-tricyclic-heteroaromatic-ring system optionally substituted on the newly formed ring where valency allows with 1-2 substitutents independently selected from F, Cl, Br, I, and R_{G-2};

R_{G-2} is alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, haloalkyl, haloalkenyl, haloalkynyl, halocycloalkyl, haloheterocycloalkyl, -OR_{G-8}, -SR_{G-8}, -$S(O)_2R_{G-8}$, -$S(O)R_{G-8}$, -$OS(O)_2R_{G-8}$, -$N(R_{G-8})_2$, -$C(O)R_{G-8}$, -$C(S)R_{G-8}$, -$C(O)OR_{G-8}$, -CN, -$C(O)N(R_{G-8})_2$, -$NR_{G-8}C(O)R_{G-8}$, -$S(O)_2N(R_{G-8})_2$, -$NR_{G-8}S(O)_2R_{G-8}$, -NO_2,

$-N(R_{G-8})C(O)N(R_{G-8})_2$, substituted alkyl, substituted alkenyl, substituted alkynyl, substituted cycloalkyl, substituted heterocycloalkyl, lactam heterocycloalkyl, phenyl, phenyl having 0-4 substituents independently selected from F, Cl, Br, I and R_{G-7}, naphthyl, or naphthyl having 0-4 substituents independently selected from F, Cl, Br, I, or R_{G-7};

provided that when G^2 adjacent to the bridge N is $C(R_{G-1})$ and the other G^2 are CH, that R_{G-1} is other than H, F, Cl, I, alkyl, substituted alkyl or alkynyl;

Each R_{G-3} is independently H, alkyl, cycloalkyl, heterocycloalkyl, alkyl substituted with 1 substituent selected from R_{G-4}, cycloalkyl substituted with 1 substituent selected from R_{G-4}, heterocycloalkyl substituted with 1 substituent selected from R_{G-4}, haloalkyl, halocycloalkyl, haloheterocycloalkyl, phenyl, or substituted phenyl;

R_{G-4} is $-OR_{G-5}$, $-SR_{G-5}$, $-N(R_{G-5})_2$, $-C(O)R_{G-5}$, $-SOR_{G-5}$, $-SO_2R_{G-5}$, $-C(O)N(R_{G-5})_2$, -CN, $-CF_3$, $-NR_{G-5}C(O)R_{G-5}$, $-S(O)_2N(R_{G-5})_2$, $-NR_{G-5}S(O)_2R_{G-5}$, or $-NO_2$;

Each R_{G-5} is independently H, alkyl, cycloalkyl, heterocycloalkyl, haloalkyl, halocycloalkyl, or haloheterocycloalkyl;

R_{G-6} is H, alkyl, haloalkyl, substituted alkyl, cycloalkyl, halocycloalkyl, substituted cycloalkyl, phenyl, or phenyl having 0-4 substituents independently selected from F, Cl, Br, I, and R_{G-7};

R_{G-7} is alkyl, substituted alkyl, haloalkyl, $-OR_{G-5}$, -CN, $-NO_2$, $-N(R_{G-3})_2$;

Each R_{G-8} is independently H, alkyl, haloalkyl, substituted alkyl, cycloalkyl, halocycloalkyl, substituted cycloalkyl, heterocycloalkyl, haloheterocycloalkyl, substituted heterocycloalkyl, phenyl, or phenyl substituted with 0-4 independently selected from F, Cl, Br, I, or R_{G-7};

wherein W is (H)



H' is N or CH;

Each R_{H-1} is independently F, Cl, Br, I, -CN, $-NO_2$, alkyl, haloalkyl, substituted alkyl, alkenyl, haloalkenyl, substituted alkenyl, alkynyl, haloalkynyl,

substituted alkynyl, cycloalkyl, halocycloalkyl, substituted cycloalkyl, heterocycloalkyl, haloheterocycloalkyl, substituted heterocycloalkyl, lactam heterocyclcoalkyl, aryl, R_5, R_6, $-OR_8$, $-SR_8$, $-SOR_8$, $-SO_2R_8$, -SCN, $-S(O)N(R_8)_2$, $-S(O)_2N(R_8)_2$, $-C(O)R_8$, $-C(O)_2R_8$, $-C(O)N(R_8)_2$, $C(R_8)$=N-OR_8, $-NC(O)R_5$, $-NC(O)R_{H-3}$, $-NC(O)R_6$, $-N(R_8)_2$, $-NR_8C(O)R_8$, $-NR_8S(O)_2R_8$, or two R_{H-1} on adjacent carbon atoms may fuse to form a 6-membered ring to give a 5-6 fused, bicyclic moiety where the 6-membered ring is optionally substituted with 1-3 substitutents selected from R_{H-2};

m_H is 0, 1, or 2;

R_{H-2} is alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, haloalkyl, haloalkenyl, haloalkynyl, halocycloalkyl, haloheterocycloalkyl, $-OR_{H-3}$, $-SR_{H-3}$, $-S(O)_2R_{H-3}$, $-S(O)R_{H-3}$, $-OS(O)_2R_{H-3}$, $-N(R_{H-3})_2$, $-C(O)R_{H-3}$, $-C(S)R_{H-3}$, $-C(O)OR_{H-3}$, -CN, $-C(O)N(R_{H-3})_2$, $-NR_{H-3}C(O)R_{H-3}$, $-S(O)_2N(R_{H-3})_2$, $-NR_{H-3}S(O)_2R_{H-3}$, $-NO_2$, $-N(R_{H-3})C(O)N(R_{H-3})_2$, substituted alkyl, substituted alkenyl, substituted alkynyl, substituted cycloalkyl, substituted heterocycloalkyl, lactam heterocycloalkyl, phenyl, phenyl having 0-4 substituents independently selected from F, Cl, Br, I and R_7, naphthyl, naphthyl having 0-4 substituents independently selected from F, Cl, Br, I, or R_7, or two R_{H-2} on adjacent carbon atoms may combine to form a three-ring-fused-5-6-6 system optionally substituted with up to 3 substituents independently selected from Br, Cl, F, I, -CN, $-NO_2$, $-CF_3$, $-N(R_{H-3})_2$, $-N(R_{H-3})C(O)R_{H-3}$, alkyl, alkenyl, and alkynyl;

Each R_{H-3} is independently H, alkyl, haloalkyl, substituted alkyl, cycloalkyl, halocycloalkyl, substituted cycloalkyl, heterocycloalkyl, haloheterocycloalkyl, substituted heterocycloalkyl, phenyl, or phenyl substituted with 0-4 independently selected from F, Cl, Br, I, or R_7;

or pharmaceutically acceptable salt, racemic mixture, or pure enantiomer thereof.

8. The method of claim 7, wherein the symptomatic relief would be to treat the mammal for pain, inflammation, cancer, or diabetes.

9. The method of claim 8, wherein the mammal would optionally receive an antiviral or antibacterial agent for a therapeutically effective interval, and wherein infection or inflammation is caused by rheumatoid arthritis; rheumatoid spondylitis; muscle degeneration; osteoporosis; osteoarthritis; psoriasis; contact dermatitis; bone

resorption diseases; atherosclerosis; Paget's disease; uveititis; gouty arthritis; inflammatory bowel disease; adult respiratory distress syndrome; Crohn's disease; rhinitis; ulcerative colitis; anaphylaxis; asthma; Reiter's syndrome; tissue rejection of a graft; ischemia reperfusion injury; brain trauma; stroke; multiple sclerosis; cerebral malaria; sepsis; septic shock; toxic shock syndrome; fever and myalgias due to infection; HIV-1, HIV-2, HIV-3; cytomegalovirus; influenza; adenovirus; a herpes virus; or herpes zoster.

10. The method of claim 8, wherein cancer is multiple myeloma; acute and chronic myelogenous leukemia; or cancer-associated cachexia, and where the mammal would optionally receive at least one of an anticancer agent or antiemetic agent for a therapeutically effective interval.

11. The method of claim 8, wherein diabetes is type I and type II diabetes, and wherein the mammal optionally receives at least one agent for the treatment of diabetes for a therapeutically effective interval.

12. The method of claim 8, wherein diabetes is associated with pancreatic beta cell destruction.

13. The method of claim 7, wherein X is O and R_1 is H.

14. The method of claim 13, wherein W is (C), (D), (E), (F), and (G).

15. The method of claim 14, wherein Azabicyclo is I, II, V and VII.

16. The method of claim 15, wherein W is 4-chlorophen-1-yl; dibenzo[b,d]thiophene-2-yl; isoquinoline-3-yl; furo[2,3-c]pyridine-5-yl; furo[3,2-c]pyridine-6; 1,3-benzodioxole-5-yl; 2,3-dihydro-1,4-benzodioxine-6-yl; 2,3-dihydro-1,4-benzodioxine-7-yl; 1,3-benzoxazole-5-yl; thieno[2,3-c]pyridine-5-yl; thieno[3,2-c]pyridine-6-yl; [1]benzothieno[3,2-c]pyridine-3-yl; 1,3-benzothiazole-6-yl; thieno[3,4-c]pyridine-6-yl; 2,3-dihydro-1-benzofuran-5-yl; 1-benzofuran-5-yl; furo[3,2-c]pyridine-6-yl; [1]benzothieno[2,3-c]pyridine-3-yl; dibenzo[b,d]furan-2-yl; 1-benzofuran-6-yl; 2-naphthyl; 1H-indole-6-yl; pyrrolo[1,2-c]pyrimidine-3-yl; 1-

benzothiophene-5-yl; 1-benzothiophene-5-yl; 1-benzothiophene-6-yl; pyrrolo[1,2-a]pyrazine-3-yl; 1H-indole-6-yl; pyrazino[1,2-a]indole-3-yl; 1,3-benzothiazole-6-yl; [1]benzofuro[2,3-c]pyridine-3-yl; [1]benzofuro[2,3-c]pyridine-3-yl; 2H-chromene-6-yl; indolizine-6-yl; and [1,3]dioxolo[4,5-c]pyridine-6-yl; any of which is optionally substituted as allowed in claim 15.

17. The method of claim 16, wherein the agonist is
N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]-4-chlorobenzamide;
N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]dibenzo[b,d]thiophene-2-carboxamide;
N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]isoquinoline-3-carboxamide;
N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]furo[2,3-c]pyridine-5-carboxamide;
N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]-1,3-benzodioxole-5-carboxamide;
N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]-2-methylfuro[2,3-c]pyridine-5-carboxamide;
N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]-2,3-dihydro-1,4-benzodioxine-6-carboxamide;
N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]-3-methylfuro[2,3-c]pyridine-5-carboxamide;
N-[(1S,2R,4R)-7-azabicyclo[2.2.1]hept-2-yl]isoquinoline-3-carboxamide;
N-[(1S,2R,4R)-7-azabicyclo[2.2.1]hept-2-yl]-3-methylfuro[2,3-c]pyridine-5-carboxamide;
N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]-1,3-benzoxazole-5-carboxamide;
N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]-2-methyl-1,3-benzoxazole-5-carboxamide;
N-[(1S,2R,4R)-7-azabicyclo[2.2.1]hept-2-yl]thieno[2,3-c]pyridine-5-carboxamide;
N-[(1S,2R,4R)-7-azabicyclo[2.2.1]hept-2-yl]thieno[3,2-c]pyridine-6-carboxamide;
N-[(1S,2R,4R)-7-azabicyclo[2.2.1]hept-2-yl]furo[2,3-c]pyridine-5-carboxamide;
N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]-3-ethylfuro[2,3-c]pyridine-5-carboxamide;
N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]-3-isopropylfuro[2,3-c]pyridine-5-carboxamide;
N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]thieno[2,3-c]pyridine-5-carboxamide;
N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]thieno[3,2-c]pyridine-6-carboxamide;
5-{[(2R)-7-azoniabicyclo[2.2.1]hept-2-ylamino]carbonyl}-3-ethylfuro[2,3-c]pyridin-6-ium dichloride;
5-{[(2R)-7-azoniabicyclo[2.2.1]hept-2-ylamino]carbonyl}-3-isopropylfuro[2,3-c]pyridin-6-ium dichloride;
N-[(3R,4S)-1-azabicyclo[2.2.1]hept-3-yl]furo[2,3-c]pyridine-5-carboxamide;
N-1-azabicyclo[2.2.2]oct-3-yl[1]benzothieno[3,2-c]pyridine-3-carboxamide;

N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]-1,3-benzothiazole-6-carboxamide;
N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]-3-chlorofuro[2,3-c]pyridine-5-carboxamide;
N-1-azabicyclo[2.2.2]oct-3-ylfuro[2,3-c]pyridine-5-carboxamide;
N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]thieno[3,4-c]pyridine-6-carboxamide;
N-[(3R,5R)-1-azabicyclo[3.2.1]oct-3-yl]-3-methylfuro[2,3-c]pyridine-5-carboxamide;
N-[(3R,4S)-1-azabicyclo[2.2.1]hept-3-yl]-3-methylfuro[2,3-c]pyridine-5-carboxamide;
N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]-2,3-dihydro-1-benzofuran-5-carboxamide;
N-[(3R,4S)-1-azabicyclo[2.2.1]hept-3-yl]thieno[2,3-c]pyridine-5-carboxamide;
N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]-1-benzofuran-5-carboxamide;
N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]furo[3,2-c]pyridine-6-carboxamide;
N-[(3R,4S)-1-azabicyclo[2.2.1]hept-3-yl]thieno[3,2-c]pyridine-6-carboxamide;
N-[(3R,4S)-1-azabicyclo[2.2.1]hept-3-yl]3-ethylfuro[2,3-c]pyridine-5-carboxamide;
N-[(3R,4S)-1-azabicyclo[2.2.1]hept-3-yl]3-isopropylfuro[2,3-c]pyridine-5-carboxamide;
N-[(1S,2R,4R)-7-azabicyclo[2.2.1]hept-2-yl]-3-chlorofuro[2,3-c]pyridine-5-carboxamide;
N-[(3R,4S)-1-azabicyclo[2.2.1]hept-3-yl]3-chlorofuro[2,3-c]pyridine-5-carboxamide;
N-[(2S,3R)-2-methyl-1-azabicyclo[2.2.2]oct-3-yl]furo[2,3-c]pyridine-5-carboxamide;
N-[(2S,3R)-2-methyl-1-azabicyclo[2.2.2]oct-3-yl]furo[3,2-c]pyridine-6-carboxamide;
N-[(3R,5R)-1-azabicyclo[3.2.1]oct-3-yl]-4-chlorobenzamide;
N-[(1S,2R,4R)-7-azabicyclo[2.2.1]hept-2-yl]thieno[3,4-c]pyridine-6-carboxamide;
N-[(1S,2R,4R)-7-azabicyclo[2.2.1]hept-2-yl]dibenzo[b,d]thiophene-2-carboxamide;
N-[(3R,4S)-1-azabicyclo[2.2.1]hept-3-yl]-1-benzofuran-5-carboxamide;
N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl][1]benzothieno[2,3-c]pyridine-3-carboxamide;
N-[(1S,2R,4R)-7-azabicyclo[2.2.1]hept-2-yl][1]benzothieno[2,3-c]pyridine-3-carboxamide;
N-[(1S,2R,4R)-7-azabicyclo[2.2.1]hept-2-yl]-1-benzofuran-5-carboxamide;
N-[(1S,2R,4R)-7-azabicyclo[2.2.1]hept-2-yl]dibenzo[b,d]furan-2-carboxamide;
N-[(3R,5R)-1-azabicyclo[3.2.1]oct-3-yl]furo[2,3-c]pyridine-5-carboxamide;
N-[(3R,5R)-1-azabicyclo[3.2.1]oct-3-yl]furo[3,2-c]pyridine-6-carboxamide;
N-[(3R,5R)-1-azabicyclo[3.2.1]oct-3-yl]-1-benzofuran-5-carboxamide;
N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]-3-bromofuro[2,3-c]pyridine-5-carboxamide;

N-[(1S,2R,4R)-7-azabicyclo[2.2.1]hept-2-yl]-3-bromofuro[2,3-c]pyridine-5-carboxamide;

N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]-1-benzofuran-6-carboxamide;

N-[(2S,3R)-2-methyl-1-azabicyclo[2.2.2]oct-3-yl]-2-naphthamide;

N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]pyrrolo[1,2-c]pyrimidine-3-carboxamide;

N-[(3R,5R)-1-azabicyclo[3.2.1]oct-3-yl]thieno[2,3-c]pyridine-5-carboxamide;

N-[(3R,5R)-1-azabicyclo[3.2.1]oct-3-yl]thieno[3,2-c]pyridine-6-carboxamide;

N-[(3R,4S)-1-azabicyclo[2.2.1]hept-3-yl]-1H-indole-6-carboxamide;

N-[(2S,3R)-2-methyl-1-azabicyclo[2.2.2]oct-3-yl]thieno[2,3-c]pyridine-5-carboxamide;

3-methyl-N-[(2S,3R)-2-methyl-1-azabicyclo[2.2.2]oct-3-yl]furo[2,3-c]pyridine-5-carboxamide;

N-[(2S,3R)-2-methyl-1-azabicyclo[2.2.2]oct-3-yl]-1-benzofuran-5-carboxamide;

N-[(2S,3R)-2-methyl-1-azabicyclo[2.2.2]oct-3-yl]thieno[3,2-c]pyridine-6-carboxamide;

N-[(2S,3R)-2-methyl-1-azabicyclo[2.2.2]oct-3-yl]pyrrolo[1,2-c]pyrimidine-3-carboxamide;

N-[(2S,3R)-2-methyl-1-azabicyclo[2.2.2]oct-3-yl]-1,3-benzothiazole-6-carboxamide;

N-[(3R,5R)-1-azabicyclo[3.2.1]oct-3-yl]pyrrolo[1,2-c]pyrimidine-3-carboxamide;

N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]-1-benzothiophene-5-carboxamide;

N-[(1S,2R,4R)-7-azabicyclo[2.2.1]hept-2-yl]pyrrolo[1,2-c]pyrimidine-3-carboxamide;

N-[(3R,4S)-1-azabicyclo[2.2.1]hept-3-yl]pyrrolo[1,2-c]pyrimidine-3-carboxamide;

N-[(3R,4S)-1-azabicyclo[2.2.1]hept-3-yl]-3-bromofuro[2,3-c]pyridine-5-carboxamide;

N-[(3R,4S)-1-azabicyclo[2.2.1]hept-3-yl]-1,3-benzodioxole-5-carboxamide;

N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]-3-bromo-1-benzofuran-5-carboxamide;

N-[(1S,2R,4R)-7-azabicyclo[2.2.1]hept-2-yl]-3-bromo-1-benzofuran-5-carboxamide;

N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]-3-bromothieno[2,3-c]pyridine-5-carboxamide;

N-[(1S,2R,4R)-7-azabicyclo[2.2.1]hept-2-yl]-3-bromothieno[2,3-c]pyridine-5-carboxamide;

N-[(3R,4S)-1-azabicyclo[2.2.1]hept-3-yl]-1-benzothiophene-5-carboxamide;

N-[(3S)-1-azabicyclo[2.2.2]oct-3-yl]furo[2,3-c]pyridine-5-carboxamide;

N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]-3-methyl-1-benzofuran-5-carboxamide;

N-[(1S,2R,4R)-7-azabicyclo[2.2.1]hept-2-yl]-3-methyl-1-benzofuran-5-carboxamide;

N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]-2-methyl-1-benzofuran-6-carboxamide;
N-[(3R,5R)-1-azabicyclo[3.2.1]oct-3-yl]-1-benzofuran-6-carboxamide;
N-[(2S,3R)-2-methyl-1-azabicyclo[2.2.2]oct-3-yl]-1-benzofuran-6-carboxamide;
N-[(2S,3R)-2-methyl-1-azabicyclo[2.2.2]oct-3-yl]-1-benzothiophene-5-carboxamide;
N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]-1-benzothiophene-6-carboxamide;
N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]pyrrolo[1,2-a]pyrazine-3-carboxamide;
N-[(3R,4S)-1-azabicyclo[2.2.1]hept-3-yl]-1-benzothiophene-6-carboxamide;
N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]-1-methyl-1H-indole-6-carboxamide;
N-[(3S)-1-azabicyclo[2.2.2]oct-3-yl]-1-benzofuran-5-carboxamide;
N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]-3-isopropyl-1-benzofuran-5-carboxamide;
N-[(1S,2R,4R)-7-azabicyclo[2.2.1]hept-2-yl]-3-isopropyl-1-benzofuran-5-carboxamide;
N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]-3-ethynylfuro[2,3-c]pyridine-5-carboxamide;
N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]-1H-indazole-6-carboxamide;
N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]-2-methyl-1-benzofuran-5-carboxamide;
N-[(1S,2R,4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-methyl-1-benzofuran-5-carboxamide;
N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]pyrazino[1,2-a]indole-3-carboxamide;
3-bromo-N-[(2S,3R)-2-methyl-1-azabicyclo[2.2.2]oct-3-yl]furo[2,3-c]pyridine-5-carboxamide;
N-[(3R,5R)-1-azabicyclo[3.2.1]oct-3-yl]pyrrolo[1,2-a]pyrazine-3-carboxamide;
N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]-7-methoxy-2-naphthamide;
N-[(1S,2R,4R)-7-azabicyclo[2.2.1]hept-2-yl]pyrrolo[1,2-a]pyrazine-3-carboxamide;
N-[(3R,5R)-1-azabicyclo[3.2.1]oct-3-yl]-1,3-benzothiazole-6-carboxamide;
N-[(3R,4S)-1-azabicyclo[2.2.1]hept-3-yl]-3-bromo-1-benzofuran-6-carboxamide;
N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl][1]benzofuro[2,3-c]pyridine-3-carboxamide;
N-[(1S,2R,4R)-7-azabicyclo[2.2.1]hept-2-yl][1]benzofuro[2,3-c]pyridine-3-carboxamide;
N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]-3-ethynyl-1-benzofuran-5-carboxamide;
N-[(1S,2R,4R)-7-azabicyclo[2.2.1]hept-2-yl]-3-ethynyl-1-benzofuran-5-carboxamide;
N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]-2H-chromene-6-carboxamide;
N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]-3-prop-1-ynyl-1-benzofuran-5-carboxamide;
N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]-2-phenyl-1,3-benzodioxole-5-carboxamide;
N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]-6-bromopyrrolo[1,2-a]pyrazine-3-carboxamide;

N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]-3-prop-1-ynylfuro[2,3-c]pyridine-5-carboxamide;

N-[(2S,3R)-2-methyl-1-azabicyclo[2.2.2]oct-3-yl]pyrrolo[1,2-a]pyrazine-3-carboxamide;

N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]indolizine-6-carboxamide;

2-amino-N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]-1,3-benzothiazole-6-carboxamide;

N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]-6-ethynylpyrrolo[1,2-a]pyrazine-3-carboxamide;

N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]-8-methoxy-2-naphthamide;

N-[(2S,3R)-2-methyl-1-azabicyclo[2.2.2]oct-3-yl]indolizine-6-carboxamide;

N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl][1,3]dioxolo[4,5-c]pyridine-6-carboxamide;

N-[(1S,2R,4R)-7-azabicyclo[2.2.1]hept-2-yl][1,3]dioxolo[4,5-c]pyridine-6-carboxamide;

N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]-3-cyano-1-benzofuran-5-carboxamide;

N-[(3R,4S)-1-azabicyclo[2.2.1]hept-3-yl][1,3]dioxolo[4,5-c]pyridine-6-carboxamide;

N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]-3-ethyl-2,3-dihydro-1,4-benzodioxine-6-carboxamide;

N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]-3-ethyl-2,3-dihydro-1,4-benzodioxine-7-carboxamide;

N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]-7-hydroxy-2-naphthamide;

N-[(1S,2R,4R)-7-azabicyclo[2.2.1]hept-2-yl]-3-ethynylfuro[2,3-c]pyridine-5-carboxamide;

N-[(1S,2R,4R)-7-azabicyclo[2.2.1]hept-2-yl]-6-chloroisoquinoline-3-carboxamide;

N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]-6-methylisoquinoline-3-carboxamide;

N-[(1S,2R,4R)-7-azabicyclo[2.2.1]hept-2-yl]-6-methylisoquinoline-3-carboxamide;

N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]-3-cyanofuro[2,3-c]pyridine-5-carboxamide;

N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]-2-naphthamide; and

N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]dibenzo[b,d]furan-2-carboxamide;

provided that the agonist is the free base or a pharmaceutically acceptable salt thereof.

18. The method of claim 17, wherein the symptomatic relief would be to treat the mammal for pain, inflammation, cancer, or diabetes.

19. The method of claim 18, wherein the mammal would optionally receive an antiviral or antibacterial agent for a therapeutically effective interval, and wherein infection or inflammation is caused by rheumatoid arthritis; rheumatoid spondylitis; muscle degeneration; osteoporosis; osteoarthritis; psoriasis; contact dermatitis; bone resorption diseases; atherosclerosis; Paget's disease; uveititis; gouty arthritis; inflammatory bowel disease; adult respiratory distress syndrome; Crohn's disease; rhinitis; ulcerative colitis; anaphylaxis; asthma; Reiter's syndrome; tissue rejection of a graft; ischemia reperfusion injury; brain trauma; stroke; multiple sclerosis; cerebral malaria; sepsis; septic shock; toxic shock syndrome; fever and myalgias due to infection; HIV-1, HIV-2, HIV-3; cytomegalovirus; influenza; adenovirus; a herpes virus; or herpes zoster.

20. The method of claim 18, wherein cancer is multiple myeloma; acute and chronic myelogenous leukemia; or cancer-associated cachexia, and where the mammal would optionally receive at least one of an anticancer agent or antiemetic agent for a therapeutically effective interval.

21. The method of claim 18, wherein diabetes is type I and type II diabetes, and wherein the mammal optionally receives at least one agent for the treatment of diabetes for a therapeutically effective interval.

22. The method of claim 18, wherein diabetes is associated with pancreatic beta cell destruction.

23. The method of claim 18, wherein the compound is
N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]dibenzo[b,d]thiophene-2-carboxamide;
N-1-azabicyclo[2.2.2]oct-3-yl[1]benzothieno[3,2-c]pyridine-3-carboxamide;
N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl][1]benzothieno[2,3-c]pyridine-3-carboxamide; and
N-[(1S,2R,4R)-7-azabicyclo[2.2.1]hept-2-yl][1]benzothieno[2,3-c]pyridine-3-carboxamide;

provided that the agonist is the free base or a pharmaceutically acceptable salt thereof.

24. The method of claim 18, wherein the compound is

N-[(2S,3R)-2-methyl-1-azabicyclo[2.2.2]oct-3-yl]-2-naphthamide;

N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]-7-methoxy-2-naphthamide;

N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]-8-methoxy-2-naphthamide;

N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]-7-hydroxy-2-naphthamide;

N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]-2-naphthamide;

N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]isoquinoline-3-carboxamide;

N-[(1S,2R,4R)-7-azabicyclo[2.2.1]hept-2-yl]isoquinoline-3-carboxamide;

N-[(1S,2R,4R)-7-azabicyclo[2.2.1]hept-2-yl]-6-chloroisoquinoline-3-carboxamide;

N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]-6-methylisoquinoline-3-carboxamide; and

N-[(1S,2R,4R)-7-azabicyclo[2.2.1]hept-2-yl]-6-methylisoquinoline-3-carboxamide;

provided that the agonist is the free base or a pharmaceutically acceptable salt thereof.

25. The method of claim 18, wherein the compound is

N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]furo[2,3-c]pyridine-5-carboxamide;

N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]furo[3,2-c]pyridine-6-carboxamide;

N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]-2-methylfuro[2,3-c]pyridine-5-carboxamide;

N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]-3-methylfuro[2,3-c]pyridine-5-carboxamide;

N-[(1S,2R,4R)-7-azabicyclo[2.2.1]hept-2-yl]-3-methylfuro[2,3-c]pyridine-5-carboxamide;

N-[(1S,2R,4R)-7-azabicyclo[2.2.1]hept-2-yl]furo[2,3-c]pyridine-5-carboxamide;

N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]-3-ethylfuro[2,3-c]pyridine-5-carboxamide;

N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]-3-isopropylfuro[2,3-c]pyridine-5-carboxamide;

N-[(3R,4S)-1-azabicyclo[2.2.1]hept-3-yl]furo[2,3-c]pyridine-5-carboxamide;

N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]-3-chlorofuro[2,3-c]pyridine-5-carboxamide;

N-1-azabicyclo[2.2.2]oct-3-ylfuro[2,3-c]pyridine-5-carboxamide;

N-[(3R,5R)-1-azabicyclo[3.2.1]oct-3-yl]-3-methylfuro[2,3-c]pyridine-5-carboxamide;

N-[(3R,4S)-1-azabicyclo[2.2.1]hept-3-yl]-3-methylfuro[2,3-c]pyridine-5-carboxamide;

N-[(3R,4S)-1-azabicyclo[2.2.1]hept-3-yl]3-ethylfuro[2,3-c]pyridine-5-carboxamide;

N-[(3R,4S)-1-azabicyclo[2.2.1]hept-3-yl]3-isopropylfuro[2,3-c]pyridine-5-carboxamide;

N-[(1S,2R,4R)-7-azabicyclo[2.2.1]hept-2-yl]-3-chlorofuro[2,3-c]pyridine-5-carboxamide;

N-[(3R,4S)-1-azabicyclo[2.2.1]hept-3-yl]3-chlorofuro[2,3-c]pyridine-5-carboxamide;

N-[(2S,3R)-2-methyl-1-azabicyclo[2.2.2]oct-3-yl]furo[2,3-c]pyridine-5-carboxamide;

N-[(2S,3R)-2-methyl-1-azabicyclo[2.2.2]oct-3-yl]furo[3,2-c]pyridine-6-carboxamide;

N-[(3R,5R)-1-azabicyclo[3.2.1]oct-3-yl]furo[3,2-c]pyridine-6-carboxamide;

N-[(3R,5R)-1-azabicyclo[3.2.1]oct-3-yl]furo[2,3-c]pyridine-5-carboxamide;

N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]-3-bromofuro[2,3-c]pyridine-5-carboxamide;

N-[(1S,2R,4R)-7-azabicyclo[2.2.1]hept-2-yl]-3-bromofuro[2,3-c]pyridine-5-carboxamide;

3-methyl-N-[(2S,3R)-2-methyl-1-azabicyclo[2.2.2]oct-3-yl]furo[2,3-c]pyridine-5-carboxamide;

N-[(3R,4S)-1-azabicyclo[2.2.1]hept-3-yl]-3-bromofuro[2,3-c]pyridine-5-carboxamide;

N-[(3S)-1-azabicyclo[2.2.2]oct-3-yl]furo[2,3-c]pyridine-5-carboxamide;

N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]-3-ethynylfuro[2,3-c]pyridine-5-carboxamide;

3-bromo-N-[(2S,3R)-2-methyl-1-azabicyclo[2.2.2]oct-3-yl]furo[2,3-c]pyridine-5-carboxamide;

N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]-3-prop-1-ynylfuro[2,3-c]pyridine-5-carboxamide;

N-[(1S,2R,4R)-7-azabicyclo[2.2.1]hept-2-yl]-3-ethynylfuro[2,3-c]pyridine-5-carboxamide; and

N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]-3-cyanofuro[2,3-c]pyridine-5-carboxamide;

provided that the agonist is the free base or a pharmaceutically acceptable salt thereof.

26. The method of claim 18, wherein the compound is

N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]-2,3-dihydro-1-benzofuran-5-carboxamide;

N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]-1-benzofuran-5-carboxamide;

N-[(3R,4S)-1-azabicyclo[2.2.1]hept-3-yl]-1-benzofuran-5-carboxamide;

N-[(1S,2R,4R)-7-azabicyclo[2.2.1]hept-2-yl]-1-benzofuran-5-carboxamide;

N-[(3R,5R)-1-azabicyclo[3.2.1]oct-3-yl]-1-benzofuran-5-carboxamide;

N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]-1-benzofuran-6-carboxamide;

N-[(2S,3R)-2-methyl-1-azabicyclo[2.2.2]oct-3-yl]-1-benzofuran-5-carboxamide;

N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]-3-bromo-1-benzofuran-5-carboxamide;

N-[(1S,2R,4R)-7-azabicyclo[2.2.1]hept-2-yl]-3-bromo-1-benzofuran-5-carboxamide;
N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]-3-methyl-1-benzofuran-5-carboxamide;
N-[(1S,2R,4R)-7-azabicyclo[2.2.1]hept-2-yl]-3-methyl-1-benzofuran-5-carboxamide;
N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]-2-methyl-1-benzofuran-6-carboxamide;
N-[(3R,5R)-1-azabicyclo[3.2.1]oct-3-yl]-1-benzofuran-6-carboxamide;
N-[(2S,3R)-2-methyl-1-azabicyclo[2.2.2]oct-3-yl]-1-benzofuran-6-carboxamide;
N-[(3S)-1-azabicyclo[2.2.2]oct-3-yl]-1-benzofuran-5-carboxamide;
N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]-3-isopropyl-1-benzofuran-5-carboxamide;
N-[(1S,2R,4R)-7-azabicyclo[2.2.1]hept-2-yl]-3-isopropyl-1-benzofuran-5-carboxamide;
N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]-2-methyl-1-benzofuran-5-carboxamide;
N-[(1S,2R,4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-methyl-1-benzofuran-5-carboxamide;
N-[(3R,4S)-1-azabicyclo[2.2.1]hept-3-yl]-3-bromo-1-benzofuran-6-carboxamide;
N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]-3-ethynyl-1-benzofuran-5-carboxamide;
N-[(1S,2R,4R)-7-azabicyclo[2.2.1]hept-2-yl]-3-ethynyl-1-benzofuran-5-carboxamide;
N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]-3-prop-1-ynyl-1-benzofuran-5-carboxamide; and
N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]-3-cyano-1-benzofuran-5-carboxamide;

provided that the agonist is the free base or a pharmaceutically acceptable salt thereof.

27. The method of claim 18, wherein the compound is
N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]pyrazino[1,2-a]indole-3-carboxamide;
N-[(3R,4S)-1-azabicyclo[2.2.1]hept-3-yl]-1H-indole-6-carboxamide;
N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]-1-methyl-1H-indole-6-carboxamide;
N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]-1-benzothiophene-5-carboxamide;
N-[(3R,4S)-1-azabicyclo[2.2.1]hept-3-yl]-1-benzothiophene-5-carboxamide;
N-[(2S,3R)-2-methyl-1-azabicyclo[2.2.2]oct-3-yl]-1-benzothiophene-5-carboxamide;
N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]-1-benzothiophene-6-carboxamide; and
N-[(3R,4S)-1-azabicyclo[2.2.1]hept-3-yl]-1-benzothiophene-6-carboxamide;

provided that the agonist is the free base or a pharmaceutically acceptable salt thereof.

28. The method of claim 18, wherein the compound is
N-[(1S,2R,4R)-7-azabicyclo[2.2.1]hept-2-yl]thieno[2,3-c]pyridine-5-carboxamide;
N-[(1S,2R,4R)-7-azabicyclo[2.2.1]hept-2-yl]thieno[3,2-c]pyridine-6-carboxamide;

N-[(1S,2R,4R)-7-azabicyclo[2.2.1]hept-2-yl]thieno[3,4-c]pyridine-6-carboxamide;
N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]thieno[2,3-c]pyridine-5-carboxamide;
N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]thieno[3,2-c]pyridine-6-carboxamide;
N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]thieno[3,4-c]pyridine-6-carboxamide;
N-[(3R,4S)-1-azabicyclo[2.2.1]hept-3-yl]thieno[2,3-c]pyridine-5-carboxamide;
N-[(3R,4S)-1-azabicyclo[2.2.1]hept-3-yl]thieno[3,2-c]pyridine-6-carboxamide;
N-[(3R,5R)-1-azabicyclo[3.2.1]oct-3-yl]thieno[2,3-c]pyridine-5-carboxamide;
N-[(3R,5R)-1-azabicyclo[3.2.1]oct-3-yl]thieno[3,2-c]pyridine-6-carboxamide;
N-[(2S,3R)-2-methyl-1-azabicyclo[2.2.2]oct-3-yl]thieno[2,3-c]pyridine-5-carboxamide;
N-[(2S,3R)-2-methyl-1-azabicyclo[2.2.2]oct-3-yl]thieno[3,2-c]pyridine-6-carboxamide;
N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]-3-bromothieno[2,3-c]pyridine-5-carboxamide; and
N-[(1S,2R,4R)-7-azabicyclo[2.2.1]hept-2-yl]-3-bromothieno[2,3-c]pyridine-5-carboxamide;

provided that the agonist is the free base or a pharmaceutically acceptable salt thereof.

29. The method of claim 18, wherein the compound is
N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]-1,3-benzothiazole-6-carboxamide;
N-[(2S,3R)-2-methyl-1-azabicyclo[2.2.2]oct-3-yl]-1,3-benzothiazole-6-carboxamide;
N-[(3R,5R)-1-azabicyclo[3.2.1]oct-3-yl]-1,3-benzothiazole-6-carboxamide;
2-amino-N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]-1,3-benzothiazole-6-carboxamide;
N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]-1H-indazole-6-carboxamide;
N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl][1,3]dioxolo[4,5-c]pyridine-6-carboxamide; and
N-[(1S,2R,4R)-7-azabicyclo[2.2.1]hept-2-yl][1,3]dioxolo[4,5-c]pyridine-6-carboxamide;

provided that the agonist is the free base or a pharmaceutically acceptable salt thereof.

30. The method of claim 18, wherein the compound is
N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]pyrrolo[1,2-c]pyrimidine-3-carboxamide;
N-[(3R,5R)-1-azabicyclo[3.2.1]oct-3-yl]pyrrolo[1,2-c]pyrimidine-3-carboxamide;
N-[(1S,2R,4R)-7-azabicyclo[2.2.1]hept-2-yl]pyrrolo[1,2-c]pyrimidine-3-carboxamide;

N-[(3R,4S)-1-azabicyclo[2.2.1]hept-3-yl]pyrrolo[1,2-c]pyrimidine-3-carboxamide;
N-[(2S,3R)-2-methyl-1-azabicyclo[2.2.2]oct-3-yl]pyrrolo[1,2-c]pyrimidine-3-carboxamide;
N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]pyrrolo[1,2-a]pyrazine-3-carboxamide;
N-[(3R,5R)-1-azabicyclo[3.2.1]oct-3-yl]pyrrolo[1,2-a]pyrazine-3-carboxamide;
N-[(1S,2R,4R)-7-azabicyclo[2.2.1]hept-2-yl]pyrrolo[1,2-a]pyrazine-3-carboxamide;
N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]-6-bromopyrrolo[1,2-a]pyrazine-3-carboxamide;
N-[(2S,3R)-2-methyl-1-azabicyclo[2.2.2]oct-3-yl]pyrrolo[1,2-a]pyrazine-3-carboxamide;
N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]-6-ethynylpyrrolo[1,2-a]pyrazine-3-carboxamide;
N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]indolizine-6-carboxamide; and
N-[(2S,3R)-2-methyl-1-azabicyclo[2.2.2]oct-3-yl]indolizine-6-carboxamide;

provided that the agonist is the free base or a pharmaceutically acceptable salt thereof.

31. A method of treating a mammal in need thereof, wherein the mammal would receive symptomatic relief by stimulating vascular angiogensis comprising the administration of an alpha 7 nAChR full agonist.

32. The method of claim 31, wherein the disease or condition is wound healing, healing bone fracture, ischemic heart disease, or stable angina pectoris.

33. The method of claim 31, wherein the wound is from surgery or burn.

34. The method of claim 31, wherein the full agonist is a compound of formula I:

Azabicyclo-N(R_1)-C(=X)-W

Formula I

wherein Azabicyclo is





V



VI



VII

X is O, or S;

R_0 is H, lower alkyl, substituted lower alkyl, or lower haloalkyl;

Each R_1 is H, alkyl, cycloalkyl, haloalkyl, substituted phenyl, or substituted naphthyl;

Each R_2 is independently F, Cl, Br, I, alkyl, substituted alkyl, haloalkyl, cycloalkyl, aryl, or R_2 is absent;

$R_{2\text{-}3}$ is H, F, Cl, Br, I, alkyl, haloalkyl, substituted alkyl, cycloalkyl, or aryl;

Each R_3 is independently H, alkyl, or substituted alkyl;

R_4 is H, alkyl, an amino protecting group, or an alkyl group having 1-3 substituents selected from F, Cl, Br, I, -OH, -CN, $-NH_2$, -NH(alkyl), or $-N(alkyl)_2$;

R_5 is 5-membered heteroaromatic mono-cyclic moieties containing within the ring 1-3 heteroatoms independently selected from the group consisting of -O-, =N-, $-N(R_{10})-$, and -S-, and having 0-1 substituent selected from R_9 and further having 0-3 substituents independently selected from F, Cl, Br, or I, or R_5 is 9-membered fused-ring moieties having a 6-membered ring fused to a 5-membered ring and having the formula



wherein L_1 is O, S, or NR_{10},



wherein L is CR_{12} or N, L_2 and L_3 are independently selected from CR_{12}, $C(R_{12})_2$, O, S, N, or NR_{10}, provided that both L_2 and L_3 are not simultaneously O, simultaneously S, or simultaneously O and S, or



wherein L is CR_{12} or N, and L_2 and L_3 are independently selected from CR_{12}, O, S, N, or NR_{10}, and each 9-membered fused-ring moiety having 0-1 substituent selected from R_9 and further having 0-3 substituent(s) independently selected from F, Cl, Br, or I, wherein the R_5 moiety attaches to other substituents as defined in formula I at any position as valency allows;

R_6 is 6-membered heteroaromatic mono-cyclic moieties containing within the ring 1-3 heteroatoms selected from =N- and having 0-1 substituent selected from R_9 and 0-3 substituent(s) independently selected from F, Cl, Br, or I, or R_6 is 10-membered heteroaromatic bi-cyclic moieties containing within one or both rings 1-3 heteroatoms selected from =N-, including, but not limited to, quinolinyl or isoquinolinyl, each 10-membered fused-ring moiety having 0-1 substituent selected from R_9 and 0-3 substituent(s) independently selected from F, Cl, Br, or I, wherein the R_6 moiety attaches to other substituents as defined in formula I at any position as valency allows;

R_7 is alkyl, substituted alkyl, haloalkyl, $-OR_{11}$, -CN, $-NO_2$, $-N(R_8)_2$;

Each R_8 is independently H, alkyl, cycloalkyl, heterocycloalkyl, alkyl substituted with 1 substituent selected from R_{13}, cycloalkyl substituted with 1 substituent selected from R_{13}, heterocycloalkyl substituted with 1 substituent selected from R_{13}, haloalkyl, halocycloalkyl, haloheterocycloalkyl, phenyl, or substituted phenyl;

R_9 is alkyl, cycloalkyl, heterocycloalkyl, haloalkyl, halocycloalkyl, haloheterocycloalkyl, $-OR_{14}$, $-SR_{14}$, $-N(R_{14})_2$, $-C(O)R_{14}$, $-C(O)N(R_{14})_2$, -CN, $-NR_{14}C(O)R_{14}$, $-S(O)_2N(R_{14})_2$, $-NR_{14}S(O)_2R_{14}$, $-NO_2$, alkyl substituted with 1-4 substituent(s) independently selected from F, Cl, Br, I, or R_{13}, cycloalkyl substituted with 1-4 substituent(s) independently selected from F, Cl, Br, I, or R_{13}, or heterocycloalkyl substituted with 1-4 substituent(s) independently selected from F, Cl, Br, I, or R_{13};

R_{10} is H, alkyl, haloalkyl, substituted alkyl, cycloalkyl, halocycloalkyl, substituted cycloalkyl, phenyl, or phenyl having 1 substituent selected from R_7 and further having 0-3 substituents independently selected from F, Cl, Br, or I;

Each R_{11} is independently H, alkyl, cycloalkyl, heterocycloalkyl, haloalkyl, halocycloalkyl, or haloheterocycloalkyl;

Each R_{12} is independently H, F, Cl, Br, I, alkyl, cycloalkyl, heterocycloalkyl, haloalkyl, halocycloalkyl, haloheterocycloalkyl, substituted alkyl, substituted cycloalkyl, substituted heterocycloalkyl, -CN, $-NO_2$, $-OR_{14}$, $-SR_{14}$, $-N(R_{14})_2$, $-C(O)R_{14}$, $-C(O)N(R_{14})_2$, $-NR_{14}C(O)R_{14}$, $-S(O)_2N(R_{14})_2$, $-NR_{14}S(O)_2R_{14}$, or a bond;

R_{13} is $-OR_{14}$, $-SR_{14}$, $-N(R_{14})_2$, $-C(O)R_{14}$, $-C(O)N(R_{14})_2$, -CN, $-CF_3$, $-NR_{14}C(O)R_{14}$, $-S(O)_2N(R_{14})_2$, $-NR_{14}S(O)_2R_{14}$, or $-NO_2$;

Each R_{14} is independently H, alkyl, cycloalkyl, heterocycloalkyl, haloalkyl, halocycloalkyl, or haloheterocycloalkyl;

wherein W is (A):



(A-1)

or



(A-2)

wherein R_{A-1a} is H, alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, haloalkyl, haloalkenyl, haloalkynyl, halocycloalkyl, haloheterocycloalkyl, substituted alkyl, substituted alkenyl, substituted alkynyl, substituted cycloalkyl, substituted heterocycloalkyl, aryl, $-R_5$, R_6, $-OR_{A-3}$, $-SR_{A-3}$, F, Cl, Br, I, $-N(R_{A-3})_2$, $-C(O)R_{A-3}$, -CN, $-C(O)N(R_{A-3})_2$, $-NR_{A-3}C(O)R_{A-3}$, $-S(O)R_{A-3}$, $-OS(O)_2R_{A-3}$, $-NR_{A-3}S(O)_2R_{A-3}$, $-NO_2$, and $-N(H)C(O)N(H)R_{A-3}$;

R_{A-1b} is $-O-R_{A-3}$, $-S-R_{A-3}$, $-S(O)-R_{A-3}$, $-C(O)-R_{A-7}$, and alkyl substituted on the ω carbon with R_{A-7};

Each R_{A-3} is independently selected from H, alkyl, haloalkyl, substituted alkyl, cycloalkyl, halocycloalkyl, substituted cycloalkyl, heterocycloalkyl, halo-heterocycloalkyl, substituted heterocycloalkyl, R_5, R_6, phenyl, or substituted phenyl;

R_{A-4} is selected from cycloalkyl, halocycloalkyl, substituted cycloalkyl, heterocycloalkyl, haloheterocycloalkyl, or substituted heterocycloalkyl;

Each R_{A-5} is independently selected from cycloalkyl, halocycloalkyl, substituted cycloalkyl, heterocycloalkyl, haloheterocycloalkyl, substituted heterocycloalkyl, R_5, R_6, phenyl, or substituted phenyl;

Each R_{A-6} is independently selected from alkyl, haloalkyl, substituted alkyl, cycloalkyl, halocycloalkyl, substituted cycloalkyl, heterocycloalkyl, halo-heterocycloalkyl, substituted heterocycloalkyl, R_5, R_6, phenyl, or substituted phenyl;

R_{A-7} is selected from aryl, R_5, or R_6;

wherein W is (B):



wherein B^0 is -O-, -S-, or -N(R_{B-0})-;

B^1 and B^2 are independently selected from =N-, or =C(R_{B-1})-;

B^3 is =N-, or =CH-, provided that when both B^1 and B^2 are =C(R_{B-1})- and B^3 is =CH-, only one =C(R_{B-1})- can be =CH-, and further provided that when B^0 is -O-, B^2 is =C(R_{B-1})- and B^3 is =C(H)-, B^1 cannot be =N-,

R_{B-0} is H, alkyl, cycloalkyl, heterocycloalkyl, haloalkyl, halocycloalkyl, haloheterocycloalkyl, substituted alkyl, substituted cycloalkyl, substituted heterocycloalkyl, or aryl, and provided that when B is (B-2) and B^3 is =N- and B^0 is N(R_{B-0}), R_{B-0} cannot be phenyl or substituted phenyl;

R_{B-1} is H, alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, haloalkyl, haloalkenyl, haloalkynyl, halocycloalkyl, haloheterocycloalkyl, substituted alkyl, substituted alkenyl, substituted alkynyl, substituted cycloalkyl, substituted heterocycloalkyl, aryl, -OR_{B-2}, -SR_{B-2}, F, Cl, Br, I, -$N(R_{B-2})_2$, -$C(O)R_{B-2}$, -$C(O)N(R_{B-2})_2$, -CN, -$NR_{B-2}C(O)R_{B-4}$, -$S(O)_2N(R_{B-2})_2$, -$OS(O)_2R_{B-4}$, -$S(O)_2R_{B-2}$, -$NR_{B-2}S(O)_2R_{B-2}$, -N(H)C(O)N(H)R_{B-2}, -NO_2, R_5, and R_6;

Each R_{B-2} is independently H, alkyl, haloalkyl, substituted alkyl, cycloalkyl, halocycloalkyl, substituted cycloalkyl, heterocycloalkyl, haloheterocycloalkyl, substituted heterocycloalkyl, R_5, R_6, phenyl, or substituted phenyl;

Each R_{B-3} is independently H, alkyl, haloalkyl, limited substituted alkyl, cycloalkyl, halocycloalkyl, substituted cycloalkyl, heterocycloalkyl, haloheterocycloalkyl, substituted heterocycloalkyl;

R_{B-4} is independently H, alkyl, cycloalkyl, heterocycloalkyl, haloalkyl, halocycloalkyl, or haloheterocycloalkyl;

wherein W is (C):

(C) is a six-membered heterocyclic ring system having 1-2 nitrogen atoms or a 10-membered bicyclic-six-six-fused-ring system having up to two nitrogen atoms

within either or both rings, provided that no nitrogen is at a bridge of the bicyclic-six-six-fused-ring system, and further having 1-2 substitutents independently selected from R_{C-1};

Each R_{C-1} is independently H, F, Cl, Br, I, alkyl, haloalkyl, substituted alkyl, alkenyl, haloalkenyl, substituted alkenyl, alkynyl, haloalkynyl, substituted alkynyl, cycloalkyl, halocycloalkyl, substituted cycloalkyl, heterocycloalkyl, haloheterocycloalkyl, substituted heterocycloalkyl, lactam heterocycloalkyl, phenyl, substituted phenyl, $-NO_2$, -CN, $-OR_{C-2}$, $-SR_{C-2}$, $-SOR_{C-2}$, $-SO_2R_{C-2}$, $-NR_{C-2}C(O)R_{C-2}$, $-N(R_{C-2})_2$, $-C(O)R_{C-2}$, $-C(O)_2R_{C-2}$, $-C(O)N(R_{C-2})_2$, -SCN, $-S(O)N(R_{C-2})_2$, $-S(O)_2N(R_{C-2})_2$, $-NR_{C-2}S(O)_2R_{C-2}$, R_5, or R_6;

Each R_{C-2} is independently H, alkyl, cycloalkyl, heterocycloalkyl, alkyl substituted with 1 substituent selected from R_{C-5}, cycloalkyl substituted with 1 substituent selected from R_{C-5}, heterocycloalkyl substituted with 1 substituent selected from R_{C-5}, haloalkyl, halocycloalkyl, haloheterocycloalkyl, phenyl, or substituted phenyl;

Each R_{C-3} is independently H, alkyl, or substituted alkyl;

R_{C-4} is H, alkyl, an amino protecting group, or an alkyl group having 1-3 substituents selected from F, Cl, Br, I, -OH, -CN, $-NH_2$, -NH(alkyl), or $-N(alkyl)_2$;

R_{C-5} is -CN, $-CF_3$, $-NO_2$, $-OR_{C-6}$, $-SR_{C-6}$, $-N(R_{C-6})_2$, $-C(O)R_{C-6}$, $-SOR_{C-6}$, $-SO_2R_{C-6}$, $-C(O)N(R_{C-6})_2$, $-NR_{C-6}C(O)R_{C-6}$, $-S(O)_2N(R_{C-6})_2$, or $-NR_{C-6}S(O)_2R_{C-6}$;

Each R_{C-6} is independently H, alkyl, cycloalkyl, heterocycloalkyl, haloalkyl, halocycloalkyl, or haloheterocycloalkyl;

wherein W is (D):



provided that the bond between the -C(=X)- group and the W group may be attached at any available carbon atom within the D group as provided in R_{D-1}, R_{D-3}, and R_{D-4};

D^0, D^1, D^2, and D^3 are N or $C(R_{D-1})$ provided that up to one of D^0, D^1, D^2, or D^3 is N and the others are $C(R_{D-1})$, further provided that when the core molecule is

attached at D^2 and D^0 or D^1 is N, D^3 is C(H), and further provided that there is only one attachment to the core molecule;

D^4---D^5---D^6 is selected from $N(R_{D-2})$-$C(R_{D-3})$=$C(R_{D-3})$, N=$C(R_{D-3})$-$C(R_{D-4})_2$, $C(R_{D-3})$=$C(R_{D-3})$-$N(R_{D-2})$, $C(R_{D-3})_2$-$N(R_{D-2})$-$C(R_{D-3})_2$, $C(R_{D-4})_2$-$C(R_{D-3})$=N, $N(R_{D-2})$-$C(R_{D-3})_2$-$C(R_{D-3})_2$, $C(R_{D-3})_2$-$C(R_{D-3})_2$-$N(R_{D-2})$, O-$C(R_{D-3})$=$C(R_{D-3})$, O-$C(R_{D-3})_2$-$C(R_{D-3})_2$, $C(R_{D-3})_2$-O-$C(R_{D-3})_2$, $C(R_{D-3})$=$C(R_{D-3})$-O, $C(R_{D-3})_2$-$C(R_{D-3})_2$-O, S-$C(R_{D-3})$=$C(R_{D-3})$, S-$C(R_{D-3})_2$-$C(R_{D-3})_2$, $C(R_{D-3})_2$-S-$C(R_{D-3})_2$, $C(R_{D-3})$=$C(R_{D-3})$-S, or $C(R_{D-3})_2$-$C(R_{D-3})_2$-S;

provided that when C(X) is attached to W at D^2 and D^6 is O, $N(R_{D-2})$, or S, D^4---D^5 is not CH=CH;

and further provided that when C(X) is attached to W at D^2 and D^4 is O, $N(R_{D-2})$, or S, D^5---D^6 is not CH=CH;

Each R_{D-1} is independently H, F, Br, I, Cl, -CN, $-CF_3$, $-OR_{D-5}$, $-SR_{D-5}$, $-N(R_{D-5})_2$, or a bond to -C(X)- provided that only one of R_{D-1}, R_{D-3}, and R_{D-4} is said bond;

Each R_{D-2} is independently H, alkyl, haloalkyl, substituted alkyl, cycloalkyl, halocycloalkyl, substituted cycloalkyl, heterocycloalkyl, haloheterocycloalkyl, substituted heterocycloalkyl, R_5, or R_6;

Each R_{D-3} is independently H, F, Br, Cl, I, alkyl, substituted alkyl, haloalkyl, alkenyl, substituted alkenyl, haloalkenyl, alkynyl, substituted alkynyl, haloalkynyl, heterocycloalkyl, substituted heterocycloalkyl, lactam heterocycloalkyl, -CN, $-NO_2$, $-OR_{D-10}$, $-C(O)N(R_{D-11})_2$, $-NR_{D-10}COR_{D-12}$, $-N(R_{D-10})_2$, $-SR_{D-10}$, $-S(O)_2R_{D-10}$, $-C(O)R_{D-12}$, $-CO_2R_{D-10}$, aryl, R_5, R_6, or a bond to -C(X)- provided that only one of R_{D-1}, R_{D-3}, and R_{D-4} is said bond;

Each R_{D-4} is independently H, F, Br, Cl, I, alkyl, substituted alkyl, haloalkyl, alkenyl, substituted alkenyl, haloalkenyl, alkynyl, substituted alkynyl, haloalkynyl, heterocycloalkyl, substituted heterocycloalkyl, lactam heterocycloalkyl, -CN, $-NO_2$, $-OR_{D-10}$, $-C(O)N(R_{D-11})_2$, $-NR_{D-10}COR_{D-12}$, $-N(R_{D-11})_2$, $-SR_{D-10}$, $-CO_2R_{D-10}$, aryl, R_5, R_6, or a bond to -C(X)- provided that only one of R_{D-1}, R_{D-3}, and R_{D-4} is said bond;

Each R_{D-5} is independently H, C_{1-3} alkyl, or C_{2-4} alkenyl;

D^7 is O, S, or $N(R_{D-2})$;

D^8 and D^9 are $C(R_{D-1})$, provided that when the molecule is attached to the phenyl moiety at D^9, D^8 is CH;

Each R_{D-10} is H, alkyl, cycloalkyl, haloalkyl, substituted phenyl, or substituted naphthyl;

Each R_{D-11} is independently H, alkyl, cycloalkyl, heterocycloalkyl, alkyl substituted with 1 substituent selected from R_{13}, cycloalkyl substituted with 1 substituent selected from R_{13}, heterocycloalkyl substituted with 1 substituent selected from R_{13}, haloalkyl, halocycloalkyl, haloheterocycloalkyl, phenyl, or substituted phenyl;

R_{D-12} is H, alkyl, substituted alkyl, cycloalkyl, haloalkyl, heterocycloalkyl, substituted heterocycloalkyl, substituted phenyl, or substituted naphthyl;

wherein W is (E):



E^0 is CH or N;

R_{E-0} is H, F, Cl, Br, I, alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, haloalkyl, haloalkenyl, haloalkynyl, halocycloalkyl, haloheterocycloalkyl, substituted alkyl, substituted alkenyl, substituted alkynyl, substituted cycloalkyl, substituted heterocycloalkyl, aryl, R_5, R_6, $-OR_{E-3}$, $-SR_{E-3}$, $-N(R_{E-3})_2$, $-C(O)R_{E-3}$, -CN, $-C(O)N(R_{E-3})_2$, $-NR_{E-3}C(O)R_{E-3}$, $-S(O)R_{E-3}$, $-S(O)R_{E-5}$, $-OS(O)_2R_{E-3}$, $-NR_{E-3}S(O)_2R_{E-3}$, $-NO_2$, or $-N(H)C(O)N(H)R_{E-3}$;

E^1 is O, CR_{E-1-1}, or $C(R_{E-1-1})_2$, provided that when E^1 is CR_{E-1-1}, one R_{E-1} is a bond to CR_{E-1-1}, and further provided that at least one of E^1 or E^2 is O;

Each R_{E-1-1} is independently H, F, Br, Cl, CN, alkyl, haloalkyl, substituted alkyl, alkynyl, cycloalkyl, $-OR_E$, or $-N(R_E)_2$, provided that at least one R_{E-1-1} is H when E^1 is $C(R_{E-1-1})_2$;

Each R_{E-1} is independently H, alkyl, substituted alkyl, haloalkyl, cycloalkyl, heterocycloalkyl, or a bond to E^1 provided that E^1 is CR_{E-1-1};

E^2 is O, CR_{E-2-2}, or $C(R_{E-2-2})_2$, provided that when E^2 is CR_{E-2-2}, one R_{E-2} is a bond to CR_{E-2-2}, and further provided that at least one of E^1 or E^2 is O;

Each R_{E-2-2} is independently H, F, Br, Cl, CN, alkyl, haloalkyl, substituted alkyl, alkynyl, cycloalkyl, $-OR_E$, or $-N(R_E)_2$, provided that at least one R_{E-2-2} is H when E^2 is $C(R_{E-2-2})_2$;

Each R_{E-2} is independently H, alkyl, substituted alkyl, haloalkyl, cycloalkyl, heterocycloalkyl, or a bond to E^2 provided that E^2 is CR_{E-2-2};

Each R_E is independently H, alkyl, cycloalkyl, heterocycloalkyl, haloalkyl, halocycloalkyl, or haloheterocycloalkyl;

Each R_{E-3} is independently H, alkyl, haloalkyl, substituted alkyl, cycloalkyl, halocycloalkyl, substituted cycloalkyl, heterocycloalkyl, haloheterocycloalkyl, substituted heterocycloalkyl, R_5, R_6, phenyl, or phenyl having 1 substituent selected from R_9 and further having 0-3 substituents independently selected from F, Cl, Br, or I or substituted phenyl;

R_{E-4} is H, haloalkyl, substituted alkyl, cycloalkyl, halocycloalkyl, substituted cycloalkyl, heterocycloalkyl, haloheterocycloalkyl, substituted heterocycloalkyl, R_5, R_6, phenyl, or substituted phenyl;

Each R_{E-5} is independently H, haloalkyl, substituted alkyl, cycloalkyl, halocycloalkyl, substituted cycloalkyl, heterocycloalkyl, haloheterocycloalkyl, substituted heterocycloalkyl, R_5, or R_6;

Each R_{E-6} is independently alkyl, haloalkyl, substituted alkyl, cycloalkyl, halocycloalkyl, substituted cycloalkyl, heterocycloalkyl, haloheterocycloalkyl, substituted heterocycloalkyl, R_5, R_6, phenyl, or phenyl having 1 substituent selected from R_9 and further having 0-3 substituents independently selected from F, Cl, Br, or I;

wherein W is (F):



(F-1) (F-2)

F^0 is C(H) wherein F^1---F^2---F^3 is selected from $O\text{-}C(R_{F-2})=N$, $O\text{-}C(R_{F-3})(R_{F-2})\text{-}N(R_{F-4})$, $O\text{-}C(R_{F-3})(R_{F-2})\text{-}S$, $O\text{-}N=C(R_{F-3})$, $O\text{-}C(R_{F-2})(R_{F-3})\text{-}O$, $S\text{-}C(R_{F-2})=N$, $S\text{-}C(R_{F-3})(R_{F-2})\text{-}N(R_{F-4})$, $S\text{-}N=C(R_{F-3})$, $N=C(R_{F-2})\text{-}O$,

$N=C(R_{F-2})-S$, $N=C(R_{F-2})-N(R_{F-4})$, $N(R_{F-4})-N=C(R_{F-3})$, $N(R_{F-4})-C(R_{F-3})(R_{F-2})-O$, $N(R_{F-4})-C(R_{F-3})(R_{F-2})-S$, $N(R_{F-4})-C(R_{F-3})(R_{F-2})-N(R_{F-4})$, $C(R_{F-3})_2-O-N(R_{F-4})$, $C(R_{F-3})_2-N(R_{F-4})-O$, $C(R_{F-3})_2-N(R_{F-4})-S$, $C(R_{F-3})=N-O$, $C(R_{F-3})=N-S$, $C(R_{F-3})=N-N(R_{F-4})$, or $C(R_{F-3})_2-C(R_{F-2})(R_{F-3})-C(R_{F-3})_2$;

F^0 is N wherein F^1---F^2---F^3 is selected from $O-C(R_{F-2})=N$, $O-C(R_{F-3})(R_{F-2})-N(R_{F-4})$, $O-C(R_{F-3})(R_{F-2})-S$, $O-N=C(R_{F-3})$ $O-C(R_{F-2})(R_{F-3})-O$, $S-C(R_{F-2})=N$, $S-C(R_{F-3})(R_{F-2})-N(R_{F-4})$, $S-N=C(R_{F-3})$, $N=C(R_{F-2})-O$, $N=C(R_{F-2})-S$, $N=C(R_{F-2})-N(R_{F-4})$, $N(R_{F-4})-N=C(R_{F-3})$, $N(R_{F-4})-C(R_{F-3})(R_{F-2})-O$, $N(R_{F-4})-C(R_{F-3})(R_{F-2})-S$, $N(R_{F-4})-C(R_{F-3})(R_{F-2})-N(R_{F-4})$, $C(R_{F-3})_2-O-N(R_{F-4})$, $C(R_{F-3})_2-N(R_{F-4})-O$, $C(R_{F-3})_2-N(R_{F-4})-S$, $C(R_{F-3})=N-O$, $C(R_{F-3})=N-S$, $C(R_{F-3})=N-N(R_{F-4})$, $C(R_{F-3})=C(R_{F-2})-C(R_{F-3})_2$, or $C(R_{F-3})_2-C(R_{F-2})(R_{F-3})-C(R_{F-3})_2$;

F^4 is $N(R_{F-7})$, O, or S;

R_{F-1} is H, F, Cl, Br, I, -CN, $-CF_3$, $-OR_{F-8}$, $-SR_{F-8}$, or $-N(R_{F-8})_2$;

R_{F-2} is H, F, alkyl, haloalkyl, substituted alkyl, lactam heterocycloalkyl, phenoxy, substituted phenoxy, R_5, R_6, $-N(R_{F-4})$-aryl, $-N(R_{F-4})$-substituted phenyl, $-N(R_{F-4})$-substituted naphthyl, -O-substituted phenyl, -O-substituted naphthyl, -S-substituted phenyl, -S-substituted naphthyl, or alkyl substituted on the ω carbon with R_{F-9};

R_{F-3} is H, F, Br, Cl, I, alkyl, substituted alkyl, haloalkyl, alkenyl, substituted alkenyl, haloalkenyl, alkynyl, substituted alkynyl, haloalkynyl, heterocycloalkyl, substituted heterocycloalkyl, lactam heterocycloalkyl, -CN, $-NO_2$, $-OR_{F-8}$, $-C(O)N(R_{F-8})_2$, $-NHR_{F-8}$, $-NR_{F-8}COR_{F-8}$, $-N(R_{F-8})_2$, $-SR_{F-8}$, $-C(O)R_{F-8}$, $-CO_2R_{F-8}$, aryl, R_5, or R_6;

R_{F-4} is H, or alkyl;

Each R_{F-5} is independently F, Br, Cl, I, alkyl, substituted alkyl, haloalkyl, alkenyl, substituted alkenyl, haloalkenyl, alkynyl, substituted alkynyl, haloalkynyl, -CN, $-CF_3$, $-OR_{F-8}$, $-C(O)NH_2$, $-NHR_{F-8}$, $-SR_{F-8}$, $-CO_2R_{F-8}$, aryl, phenoxy, substituted phenoxy, heteroaryl, $-N(R_{F-4})$-aryl, or -O-substituted aryl;

One of R_{F-6} is H, alkyl, substituted alkyl, haloalkyl, alkenyl, substituted alkenyl, haloalkenyl, alkynyl, substituted alkynyl, haloalkynyl, -CN, F, Br, Cl, I, $-OR_{F-8}$, $-C(O)NH_2$, $-NHR_{F-8}$, $-SR_{F-8}$, $-CO_2R_{F-8}$, aryl, R_5, or R_6, and each of the other two R_{F-6} is independently selected from alkyl, substituted alkyl, haloalkyl, alkenyl,

substituted alkenyl, haloalkenyl, alkynyl, substituted alkynyl, haloalkynyl, -CN, F, Br, Cl, I, $-OR_{F-8}$, $-C(O)NH_2$, $-NHR_{F-8}$, $-SR_{F-8}$, $-CO_2R_{F-8}$, aryl, R_5, or R_6;

R_{F-7} is H, alkyl, haloalkyl, substituted alkyl, cycloalkyl, halocycloalkyl, substituted cycloalkyl, phenyl, or phenyl having 1 substituent selected from R_9 and further having 0-3 substituents independently selected from F, Cl, Br, or I;

R_{F-8} is H, alkyl, substituted alkyl, cycloalkyl, haloalkyl, heterocycloalkyl, substituted heterocycloalkyl, substituted phenyl, or substituted naphthyl;

R_{F-9} is aryl, R_5, or R_6;

wherein W is (G):



G^1 is N or CH;

Each G^2 is N or $C(R_{G-1})$, provided that no more than one G^2 is N;

Each R_{G-1} is independently H, alkyl, substituted alkyl, haloalkyl, alkenyl, substituted alkenyl, haloalkenyl, alkynyl, substituted alkynyl, haloalkynyl, -CN, $-NO_2$, F, Br, Cl, I, $-C(O)N(R_{G-3})_2$, $-N(R_{G-3})_2$, $-SR_{G-6}$, $-S(O)_2R_{G-6}$, $-OR_{G-6}$, $-C(O)R_{G-6}$, $-CO_2R_{G-6}$, aryl, R_5, R_6, or two R_{G-1} on adjacent carbon atoms may combine for W to be a 6-5-6 fused-tricyclic-heteroaromatic-ring system optionally substituted on the newly formed ring where valency allows with 1-2 substitutents independently selected from F, Cl, Br, I, and R_{G-2};

R_{G-2} is alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, haloalkyl, haloalkenyl, haloalkynyl, halocycloalkyl, haloheterocycloalkyl, $-OR_{G-8}$, $-SR_{G-8}$, $-S(O)_2R_{G-8}$, $-S(O)R_{G-8}$, $-OS(O)_2R_{G-8}$, $-N(R_{G-8})_2$, $-C(O)R_{G-8}$, $-C(S)R_{G-8}$, $-C(O)OR_{G-8}$, -CN, $-C(O)N(R_{G-8})_2$, $-NR_{G-8}C(O)R_{G-8}$, $-S(O)_2N(R_{G-8})_2$, $-NR_{G-8}S(O)_2R_{G-8}$, $-NO_2$, $-N(R_{G-8})C(O)N(R_{G-8})_2$, substituted alkyl, substituted alkenyl, substituted alkynyl, substituted cycloalkyl, substituted heterocycloalkyl, lactam heterocycloalkyl, phenyl, phenyl having 0-4 substituents independently selected from F, Cl, Br, I and R_{G-7}, naphthyl, or naphthyl having 0-4 substituents independently selected from F, Cl, Br, I, or R_{G-7};

provided that when G^2 adjacent to the bridge N is $C(R_{G-1})$ and the other G^2 are CH, that R_{G-1} is other than H, F, Cl, I, alkyl, substituted alkyl or alkynyl;

Each R_{G-3} is independently H, alkyl, cycloalkyl, heterocycloalkyl, alkyl substituted with 1 substituent selected from R_{G-4}, cycloalkyl substituted with 1 substituent selected from R_{G-4}, heterocycloalkyl substituted with 1 substituent selected from R_{G-4}, haloalkyl, halocycloalkyl, haloheterocycloalkyl, phenyl, or substituted phenyl;

R_{G-4} is $-OR_{G-5}$, $-SR_{G-5}$, $-N(R_{G-5})_2$, $-C(O)R_{G-5}$, $-SOR_{G-5}$, $-SO_2R_{G-5}$, $-C(O)N(R_{G-5})_2$, -CN, $-CF_3$, $-NR_{G-5}C(O)R_{G-5}$, $-S(O)_2N(R_{G-5})_2$, $-NR_{G-5}S(O)_2R_{G-5}$, or $-NO_2$;

Each R_{G-5} is independently H, alkyl, cycloalkyl, heterocycloalkyl, haloalkyl, halocycloalkyl, or haloheterocycloalkyl;

R_{G-6} is H, alkyl, haloalkyl, substituted alkyl, cycloalkyl, halocycloalkyl, substituted cycloalkyl, phenyl, or phenyl having 0-4 substituents independently selected from F, Cl, Br, I, and R_{G-7};

R_{G-7} is alkyl, substituted alkyl, haloalkyl, $-OR_{G-5}$, -CN, $-NO_2$, $-N(R_{G-3})_2$;

Each R_{G-8} is independently H, alkyl, haloalkyl, substituted alkyl, cycloalkyl, halocycloalkyl, substituted cycloalkyl, heterocycloalkyl, haloheterocycloalkyl, substituted heterocycloalkyl, phenyl, or phenyl substituted with 0-4 independently selected from F, Cl, Br, I, or R_{G-7};

wherein W is (H)



H' is N or CH;

Each R_{H-1} is independently F, Cl, Br, I, -CN, $-NO_2$, alkyl, haloalkyl, substituted alkyl, alkenyl, haloalkenyl, substituted alkenyl, alkynyl, haloalkynyl, substituted alkynyl, cycloalkyl, halocycloalkyl, substituted cycloalkyl, heterocycloalkyl, haloheterocycloalkyl, substituted heterocycloalkyl, lactam heterocyclcoalkyl, aryl, R_5, R_6, $-OR_8$, $-SR_8$, $-SOR_8$, $-SO_2R_8$, -SCN, $-S(O)N(R_8)_2$, $-S(O)_2N(R_8)_2$, $-C(O)R_8$, $-C(O)_2R_8$, $-C(O)N(R_8)_2$, $C(R_8)$=N-OR_8, $-NC(O)R_5$, $-NC(O)R_{H-3}$, $-NC(O)R_6$, $-N(R_8)_2$, $-NR_8C(O)R_8$, $-NR_8S(O)_2R_8$, or two R_{H-1} on adjacent carbon atoms may fuse to form a 6-membered ring to give a 5-6 fused, bicyclic moiety

where the 6-membered ring is optionally substituted with 1-3 substitutents selected from R_{H-2};

m_H is 0, 1, or 2;

R_{H-2} is alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, haloalkyl, haloalkenyl, haloalkynyl, halocycloalkyl, haloheterocycloalkyl, $-OR_{H-3}$, $-SR_{H-3}$, $-S(O)_2R_{H-3}$, $-S(O)R_{H-3}$, $-OS(O)_2R_{H-3}$, $-N(R_{H-3})_2$, $-C(O)R_{H-3}$, $-C(S)R_{H-3}$, $-C(O)OR_{H-3}$, -CN, $-C(O)N(R_{H-3})_2$, $-NR_{H-3}C(O)R_{H-3}$, $-S(O)_2N(R_{H-3})_2$, $-NR_{H-3}S(O)_2R_{H-3}$, $-NO_2$, $-N(R_{H-3})C(O)N(R_{H-3})_2$, substituted alkyl, substituted alkenyl, substituted alkynyl, substituted cycloalkyl, substituted heterocycloalkyl, lactam heterocycloalkyl, phenyl, phenyl having 0-4 substituents independently selected from F, Cl, Br, I and R_7, naphthyl, naphthyl having 0-4 substituents independently selected from F, Cl, Br, I, or R_7, or two R_{H-2} on adjacent carbon atoms may combine to form a three-ring-fused-5-6-6 system optionally substituted with up to 3 substituents independently selected from Br, Cl, F, I, -CN, $-NO_2$, $-CF_3$, $-N(R_{H-3})_2$, $-N(R_{H-3})C(O)R_{H-3}$, alkyl, alkenyl, and alkynyl;

Each R_{H-3} is independently H, alkyl, haloalkyl, substituted alkyl, cycloalkyl, halocycloalkyl, substituted cycloalkyl, heterocycloalkyl, haloheterocycloalkyl, substituted heterocycloalkyl, phenyl, or phenyl substituted with 0-4 independently selected from F, Cl, Br, I, or R_7;

or pharmaceutically acceptable salt, racemic mixture, or pure enantiomer thereof.

35. The method of claim 34, wherein the disease or condition is wound healing, healing bone fracture, ischemic heart disease, or stable angina pectoris.

36. The method of claim 34, wherein the wound is from surgery or burn.

37. The method of claim 34, wherein X is O and R_1 is H.

38. The method of claim 37, wherein W is (C), (D), (E), (F), and (G).

39. The method of claim 38, wherein Azabicyclo is I, II, V and VII.

40. The method of claim 39, wherein W is 4-chlorophen-1-yl; dibenzo[b,d]thiophene-2-yl; isoquinoline-3-yl; furo[2,3-c]pyridine-5-yl; furo[3,2-c]pyridine-6; 1,3-benzodioxole-5-yl; 2,3-dihydro-1,4-benzodioxine-6-yl; 2,3-dihydro-1,4-benzodioxine-7-yl; 1,3-benzoxazole-5-yl; thieno[2,3-c]pyridine-5-yl; thieno[3,2-c]pyridine-6-yl; [1]benzothieno[3,2-c]pyridine-3-yl; 1,3-benzothiazole-6-yl; thieno[3,4-c]pyridine-6-yl; 2,3-dihydro-1-benzofuran-5-yl; 1-benzofuran-5-yl; furo[3,2-c]pyridine-6-yl; [1]benzothieno[2,3-c]pyridine-3-yl; dibenzo[b,d]furan-2-yl; 1-benzofuran-6-yl; 2-naphthyl; 1H-indole-6-yl; pyrrolo[1,2-c]pyrimidine-3-yl; 1-benzothiophene-5-yl; 1-benzothiophene-5-yl; 1-benzothiophene-6-yl; pyrrolo[1,2-a]pyrazine-3-yl; 1H-indole-6-yl; pyrazino[1,2-a]indole-3-yl; 1,3-benzothiazole-6-yl; [1]benzofuro[2,3-c]pyridine-3-yl; [1]benzofuro[2,3-c]pyridine-3-yl; 2H-chromene-6-yl; indolizine-6-yl; and [1,3]dioxolo[4,5-c]pyridine-6-yl; any of which is optionally substituted as allowed in claim 39.

41. The method of claim 40, wherein the agonist is
N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]-4-chlorobenzamide;
N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]dibenzo[b,d]thiophene-2-carboxamide;
N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]isoquinoline-3-carboxamide;
N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]furo[2,3-c]pyridine-5-carboxamide;
N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]-1,3-benzodioxole-5-carboxamide;
N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]-2-methylfuro[2,3-c]pyridine-5-carboxamide;
N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]-2,3-dihydro-1,4-benzodioxine-6-carboxamide;
N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]-3-methylfuro[2,3-c]pyridine-5-carboxamide;
N-[(1S,2R,4R)-7-azabicyclo[2.2.1]hept-2-yl]isoquinoline-3-carboxamide;
N-[(1S,2R,4R)-7-azabicyclo[2.2.1]hept-2-yl]-3-methylfuro[2,3-c]pyridine-5-carboxamide;
N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]-1,3-benzoxazole-5-carboxamide;
N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]-2-methyl-1,3-benzoxazole-5-carboxamide;
N-[(1S,2R,4R)-7-azabicyclo[2.2.1]hept-2-yl]thieno[2,3-c]pyridine-5-carboxamide;
N-[(1S,2R,4R)-7-azabicyclo[2.2.1]hept-2-yl]thieno[3,2-c]pyridine-6-carboxamide;
N-[(1S,2R,4R)-7-azabicyclo[2.2.1]hept-2-yl]furo[2,3-c]pyridine-5-carboxamide;
N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]-3-ethylfuro[2,3-c]pyridine-5-carboxamide;
N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]-3-isopropylfuro[2,3-c]pyridine-5-carboxamide;

N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]thieno[2,3-c]pyridine-5-carboxamide;
N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]thieno[3,2-c]pyridine-6-carboxamide;
5-{[(2R)-7-azoniabicyclo[2.2.1]hept-2-ylamino]carbonyl}-3-ethylfuro[2,3-c]pyridin-6-ium dichloride;
5-{[(2R)-7-azoniabicyclo[2.2.1]hept-2-ylamino]carbonyl}-3-isopropylfuro[2,3-c]pyridin-6-ium dichloride;
N-[(3R,4S)-1-azabicyclo[2.2.1]hept-3-yl]furo[2,3-c]pyridine-5-carboxamide;
N-1-azabicyclo[2.2.2]oct-3-yl[1]benzothieno[3,2-c]pyridine-3-carboxamide;
N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]-1,3-benzothiazole-6-carboxamide;
N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]-3-chlorofuro[2,3-c]pyridine-5-carboxamide;
N-1-azabicyclo[2.2.2]oct-3-ylfuro[2,3-c]pyridine-5-carboxamide;
N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]thieno[3,4-c]pyridine-6-carboxamide;
N-[(3R,5R)-1-azabicyclo[3.2.1]oct-3-yl]-3-methylfuro[2,3-c]pyridine-5-carboxamide;
N-[(3R,4S)-1-azabicyclo[2.2.1]hept-3-yl]-3-methylfuro[2,3-c]pyridine-5-carboxamide;
N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]-2,3-dihydro-1-benzofuran-5-carboxamide;
N-[(3R,4S)-1-azabicyclo[2.2.1]hept-3-yl]thieno[2,3-c]pyridine-5-carboxamide;
N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]-1-benzofuran-5-carboxamide;
N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]furo[3,2-c]pyridine-6-carboxamide;
N-[(3R,4S)-1-azabicyclo[2.2.1]hept-3-yl]thieno[3,2-c]pyridine-6-carboxamide;
N-[(3R,4S)-1-azabicyclo[2.2.1]hept-3-yl]3-ethylfuro[2,3-c]pyridine-5-carboxamide;
N-[(3R,4S)-1-azabicyclo[2.2.1]hept-3-yl]3-isopropylfuro[2,3-c]pyridine-5-carboxamide;
N-[(1S,2R,4R)-7-azabicyclo[2.2.1]hept-2-yl]-3-chlorofuro[2,3-c]pyridine-5-carboxamide;
N-[(3R,4S)-1-azabicyclo[2.2.1]hept-3-yl]3-chlorofuro[2,3-c]pyridine-5-carboxamide;
N-[(2S,3R)-2-methyl-1-azabicyclo[2.2.2]oct-3-yl]furo[2,3-c]pyridine-5-carboxamide;
N-[(2S,3R)-2-methyl-1-azabicyclo[2.2.2]oct-3-yl]furo[3,2-c]pyridine-6-carboxamide;
N-[(3R,5R)-1-azabicyclo[3.2.1]oct-3-yl]-4-chlorobenzamide;
N-[(1S,2R,4R)-7-azabicyclo[2.2.1]hept-2-yl]thieno[3,4-c]pyridine-6-carboxamide;
N-[(1S,2R,4R)-7-azabicyclo[2.2.1]hept-2-yl]dibenzo[b,d]thiophene-2-carboxamide;
N-[(3R,4S)-1-azabicyclo[2.2.1]hept-3-yl]-1-benzofuran-5-carboxamide;
N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl][1]benzothieno[2,3-c]pyridine-3-carboxamide;

N-[(1S,2R,4R)-7-azabicyclo[2.2.1]hept-2-yl][1]benzothieno[2,3-c]pyridine-3-carboxamide;

N-[(1S,2R,4R)-7-azabicyclo[2.2.1]hept-2-yl]-1-benzofuran-5-carboxamide;

N-[(1S,2R,4R)-7-azabicyclo[2.2.1]hept-2-yl]dibenzo[b,d]furan-2-carboxamide;

N-[(3R,5R)-1-azabicyclo[3.2.1]oct-3-yl]furo[2,3-c]pyridine-5-carboxamide;

N-[(3R,5R)-1-azabicyclo[3.2.1]oct-3-yl]furo[3,2-c]pyridine-6-carboxamide;

N-[(3R,5R)-1-azabicyclo[3.2.1]oct-3-yl]-1-benzofuran-5-carboxamide;

N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]-3-bromofuro[2,3-c]pyridine-5-carboxamide;

N-[(1S,2R,4R)-7-azabicyclo[2.2.1]hept-2-yl]-3-bromofuro[2,3-c]pyridine-5-carboxamide;

N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]-1-benzofuran-6-carboxamide;

N-[(2S,3R)-2-methyl-1-azabicyclo[2.2.2]oct-3-yl]-2-naphthamide;

N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]pyrrolo[1,2-c]pyrimidine-3-carboxamide;

N-[(3R,5R)-1-azabicyclo[3.2.1]oct-3-yl]thieno[2,3-c]pyridine-5-carboxamide;

N-[(3R,5R)-1-azabicyclo[3.2.1]oct-3-yl]thieno[3,2-c]pyridine-6-carboxamide;

N-[(3R,4S)-1-azabicyclo[2.2.1]hept-3-yl]-1H-indole-6-carboxamide;

N-[(2S,3R)-2-methyl-1-azabicyclo[2.2.2]oct-3-yl]thieno[2,3-c]pyridine-5-carboxamide;

3-methyl-N-[(2S,3R)-2-methyl-1-azabicyclo[2.2.2]oct-3-yl]furo[2,3-c]pyridine-5-carboxamide;

N-[(2S,3R)-2-methyl-1-azabicyclo[2.2.2]oct-3-yl]-1-benzofuran-5-carboxamide;

N-[(2S,3R)-2-methyl-1-azabicyclo[2.2.2]oct-3-yl]thieno[3,2-c]pyridine-6-carboxamide;

N-[(2S,3R)-2-methyl-1-azabicyclo[2.2.2]oct-3-yl]pyrrolo[1,2-c]pyrimidine-3-carboxamide;

N-[(2S,3R)-2-methyl-1-azabicyclo[2.2.2]oct-3-yl]-1,3-benzothiazole-6-carboxamide;

N-[(3R,5R)-1-azabicyclo[3.2.1]oct-3-yl]pyrrolo[1,2-c]pyrimidine-3-carboxamide;

N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]-1-benzothiophene-5-carboxamide;

N-[(1S,2R,4R)-7-azabicyclo[2.2.1]hept-2-yl]pyrrolo[1,2-c]pyrimidine-3-carboxamide;

N-[(3R,4S)-1-azabicyclo[2.2.1]hept-3-yl]pyrrolo[1,2-c]pyrimidine-3-carboxamide;

N-[(3R,4S)-1-azabicyclo[2.2.1]hept-3-yl]-3-bromofuro[2,3-c]pyridine-5-carboxamide;

N-[(3R,4S)-1-azabicyclo[2.2.1]hept-3-yl]-1,3-benzodioxole-5-carboxamide;

N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]-3-bromo-1-benzofuran-5-carboxamide;

N-[(1S,2R,4R)-7-azabicyclo[2.2.1]hept-2-yl]-3-bromo-1-benzofuran-5-carboxamide;
N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]-3-bromothieno[2,3-c]pyridine-5-carboxamide;
N-[(1S,2R,4R)-7-azabicyclo[2.2.1]hept-2-yl]-3-bromothieno[2,3-c]pyridine-5-carboxamide;
N-[(3R,4S)-1-azabicyclo[2.2.1]hept-3-yl]-1-benzothiophene-5-carboxamide;
N-[(3S)-1-azabicyclo[2.2.2]oct-3-yl]furo[2,3-c]pyridine-5-carboxamide;
N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]-3-methyl-1-benzofuran-5-carboxamide;
N-[(1S,2R,4R)-7-azabicyclo[2.2.1]hept-2-yl]-3-methyl-1-benzofuran-5-carboxamide;
N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]-2-methyl-1-benzofuran-6-carboxamide;
N-[(3R,5R)-1-azabicyclo[3.2.1]oct-3-yl]-1-benzofuran-6-carboxamide;
N-[(2S,3R)-2-methyl-1-azabicyclo[2.2.2]oct-3-yl]-1-benzofuran-6-carboxamide;
N-[(2S,3R)-2-methyl-1-azabicyclo[2.2.2]oct-3-yl]-1-benzothiophene-5-carboxamide;
N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]-1-benzothiophene-6-carboxamide;
N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]pyrrolo[1,2-a]pyrazine-3-carboxamide;
N-[(3R,4S)-1-azabicyclo[2.2.1]hept-3-yl]-1-benzothiophene-6-carboxamide;
N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]-1-methyl-1H-indole-6-carboxamide;
N-[(3S)-1-azabicyclo[2.2.2]oct-3-yl]-1-benzofuran-5-carboxamide;
N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]-3-isopropyl-1-benzofuran-5-carboxamide;
N-[(1S,2R,4R)-7-azabicyclo[2.2.1]hept-2-yl]-3-isopropyl-1-benzofuran-5-carboxamide;
N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]-3-ethynylfuro[2,3-c]pyridine-5-carboxamide;
N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]-1H-indazole-6-carboxamide;
N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]-2-methyl-1-benzofuran-5-carboxamide;
N-[(1S,2R,4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-methyl-1-benzofuran-5-carboxamide;
N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]pyrazino[1,2-a]indole-3-carboxamide;
3-bromo-N-[(2S,3R)-2-methyl-1-azabicyclo[2.2.2]oct-3-yl]furo[2,3-c]pyridine-5-carboxamide;
N-[(3R,5R)-1-azabicyclo[3.2.1]oct-3-yl]pyrrolo[1,2-a]pyrazine-3-carboxamide;
N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]-7-methoxy-2-naphthamide;
N-[(1S,2R,4R)-7-azabicyclo[2.2.1]hept-2-yl]pyrrolo[1,2-a]pyrazine-3-carboxamide;
N-[(3R,5R)-1-azabicyclo[3.2.1]oct-3-yl]-1,3-benzothiazole-6-carboxamide;
N-[(3R,4S)-1-azabicyclo[2.2.1]hept-3-yl]-3-bromo-1-benzofuran-6-carboxamide;
N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl][1]benzofuro[2,3-c]pyridine-3-carboxamide;

N-[(1S,2R,4R)-7-azabicyclo[2.2.1]hept-2-yl][1]benzofuro[2,3-c]pyridine-3-carboxamide;

N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]-3-ethynyl-1-benzofuran-5-carboxamide;

N-[(1S,2R,4R)-7-azabicyclo[2.2.1]hept-2-yl]-3-ethynyl-1-benzofuran-5-carboxamide;

N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]-2H-chromene-6-carboxamide;

N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]-3-prop-1-ynyl-1-benzofuran-5-carboxamide;

N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]-2-phenyl-1,3-benzodioxole-5-carboxamide;

N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]-6-bromopyrrolo[1,2-a]pyrazine-3-carboxamide;

N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]-3-prop-1-ynylfuro[2,3-c]pyridine-5-carboxamide;

N-[(2S,3R)-2-methyl-1-azabicyclo[2.2.2]oct-3-yl]pyrrolo[1,2-a]pyrazine-3-carboxamide;

N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]indolizine-6-carboxamide;

2-amino-N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]-1,3-benzothiazole-6-carboxamide;

N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]-6-ethynylpyrrolo[1,2-a]pyrazine-3-carboxamide;

N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]-8-methoxy-2-naphthamide;

N-[(2S,3R)-2-methyl-1-azabicyclo[2.2.2]oct-3-yl]indolizine-6-carboxamide;

N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl][1,3]dioxolo[4,5-c]pyridine-6-carboxamide;

N-[(1S,2R,4R)-7-azabicyclo[2.2.1]hept-2-yl][1,3]dioxolo[4,5-c]pyridine-6-carboxamide;

N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]-3-cyano-1-benzofuran-5-carboxamide;

N-[(3R,4S)-1-azabicyclo[2.2.1]hept-3-yl][1,3]dioxolo[4,5-c]pyridine-6-carboxamide;

N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]-3-ethyl-2,3-dihydro-1,4-benzodioxine-6-carboxamide;

N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]-3-ethyl-2,3-dihydro-1,4-benzodioxine-7-carboxamide;

N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]-7-hydroxy-2-naphthamide;

N-[(1S,2R,4R)-7-azabicyclo[2.2.1]hept-2-yl]-3-ethynylfuro[2,3-c]pyridine-5-carboxamide;

N-[(1S,2R,4R)-7-azabicyclo[2.2.1]hept-2-yl]-6-chloroisoquinoline-3-carboxamide;

N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]-6-methylisoquinoline-3-carboxamide;

N-[(1S,2R,4R)-7-azabicyclo[2.2.1]hept-2-yl]-6-methylisoquinoline-3-carboxamide;

N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]-3-cyanofuro[2,3-c]pyridine-5-carboxamide;

N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]-2-naphthamide; and
N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]dibenzo[b,d]furan-2-carboxamide;

provided that the agonist is the free base or a pharmaceutically acceptable salt thereof.

42. The method of claim 41, wherein the disease or condition is wound healing, healing bone fracture, ischemic heart disease, or stable angina pectoris.

43. The method of claim 41, wherein the wound is from surgery or burn.

44. The method of claim 41, wherein the compound is
N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]dibenzo[b,d]thiophene-2-carboxamide;
N-1-azabicyclo[2.2.2]oct-3-yl[1]benzothieno[3,2-c]pyridine-3-carboxamide;
N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl][1]benzothieno[2,3-c]pyridine-3-carboxamide; and
N-[(1S,2R,4R)-7-azabicyclo[2.2.1]hept-2-yl][1]benzothieno[2,3-c]pyridine-3-carboxamide;

provided that the agonist is the free base or a pharmaceutically acceptable salt thereof.

45. The method of claim 41, wherein the compound is
N-[(2S,3R)-2-methyl-1-azabicyclo[2.2.2]oct-3-yl]-2-naphthamide;
N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]-7-methoxy-2-naphthamide;
N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]-8-methoxy-2-naphthamide;
N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]-7-hydroxy-2-naphthamide;
N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]-2-naphthamide;
N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]isoquinoline-3-carboxamide;
N-[(1S,2R,4R)-7-azabicyclo[2.2.1]hept-2-yl]isoquinoline-3-carboxamide;
N-[(1S,2R,4R)-7-azabicyclo[2.2.1]hept-2-yl]-6-chloroisoquinoline-3-carboxamide;
N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]-6-methylisoquinoline-3-carboxamide; and
N-[(1S,2R,4R)-7-azabicyclo[2.2.1]hept-2-yl]-6-methylisoquinoline-3-carboxamide;

provided that the agonist is the free base or a pharmaceutically acceptable salt thereof.

46. The method of claim 41, wherein the compound is
N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]furo[2,3-c]pyridine-5-carboxamide;

N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]furo[3,2-c]pyridine-6-carboxamide;
N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]-2-methylfuro[2,3-c]pyridine-5-carboxamide;
N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]-3-methylfuro[2,3-c]pyridine-5-carboxamide;
N-[(1S,2R,4R)-7-azabicyclo[2.2.1]hept-2-yl]-3-methylfuro[2,3-c]pyridine-5-carboxamide;
N-[(1S,2R,4R)-7-azabicyclo[2.2.1]hept-2-yl]furo[2,3-c]pyridine-5-carboxamide;
N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]-3-ethylfuro[2,3-c]pyridine-5-carboxamide;
N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]-3-isopropylfuro[2,3-c]pyridine-5-carboxamide;
N-[(3R,4S)-1-azabicyclo[2.2.1]hept-3-yl]furo[2,3-c]pyridine-5-carboxamide;
N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]-3-chlorofuro[2,3-c]pyridine-5-carboxamide;
N-1-azabicyclo[2.2.2]oct-3-ylfuro[2,3-c]pyridine-5-carboxamide;
N-[(3R,5R)-1-azabicyclo[3.2.1]oct-3-yl]-3-methylfuro[2,3-c]pyridine-5-carboxamide;
N-[(3R,4S)-1-azabicyclo[2.2.1]hept-3-yl]-3-methylfuro[2,3-c]pyridine-5-carboxamide;
N-[(3R,4S)-1-azabicyclo[2.2.1]hept-3-yl]3-ethylfuro[2,3-c]pyridine-5-carboxamide;
N-[(3R,4S)-1-azabicyclo[2.2.1]hept-3-yl]3-isopropylfuro[2,3-c]pyridine-5-carboxamide;
N-[(1S,2R,4R)-7-azabicyclo[2.2.1]hept-2-yl]-3-chlorofuro[2,3-c]pyridine-5-carboxamide;
N-[(3R,4S)-1-azabicyclo[2.2.1]hept-3-yl]3-chlorofuro[2,3-c]pyridine-5-carboxamide;
N-[(2S,3R)-2-methyl-1-azabicyclo[2.2.2]oct-3-yl]furo[2,3-c]pyridine-5-carboxamide;
N-[(2S,3R)-2-methyl-1-azabicyclo[2.2.2]oct-3-yl]furo[3,2-c]pyridine-6-carboxamide;
N-[(3R,5R)-1-azabicyclo[3.2.1]oct-3-yl]furo[3,2-c]pyridine-6-carboxamide;
N-[(3R,5R)-1-azabicyclo[3.2.1]oct-3-yl]furo[2,3-c]pyridine-5-carboxamide;
N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]-3-bromofuro[2,3-c]pyridine-5-carboxamide;
N-[(1S,2R,4R)-7-azabicyclo[2.2.1]hept-2-yl]-3-bromofuro[2,3-c]pyridine-5-carboxamide;
3-methyl-N-[(2S,3R)-2-methyl-1-azabicyclo[2.2.2]oct-3-yl]furo[2,3-c]pyridine-5-carboxamide;
N-[(3R,4S)-1-azabicyclo[2.2.1]hept-3-yl]-3-bromofuro[2,3-c]pyridine-5-carboxamide;
N-[(3S)-1-azabicyclo[2.2.2]oct-3-yl]furo[2,3-c]pyridine-5-carboxamide;
N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]-3-ethynylfuro[2,3-c]pyridine-5-carboxamide;

3-bromo-N-[(2S,3R)-2-methyl-1-azabicyclo[2.2.2]oct-3-yl]furo[2,3-c]pyridine-5-carboxamide;

N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]-3-prop-1-ynylfuro[2,3-c]pyridine-5-carboxamide;

N-[(1S,2R,4R)-7-azabicyclo[2.2.1]hept-2-yl]-3-ethynylfuro[2,3-c]pyridine-5-carboxamide; and

N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]-3-cyanofuro[2,3-c]pyridine-5-carboxamide;

provided that the agonist is the free base or a pharmaceutically acceptable salt thereof.

47. The method of claim 41, wherein the compound is

N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]-2,3-dihydro-1-benzofuran-5-carboxamide;

N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]-1-benzofuran-5-carboxamide;

N-[(3R,4S)-1-azabicyclo[2.2.1]hept-3-yl]-1-benzofuran-5-carboxamide;

N-[(1S,2R,4R)-7-azabicyclo[2.2.1]hept-2-yl]-1-benzofuran-5-carboxamide;

N-[(3R,5R)-1-azabicyclo[3.2.1]oct-3-yl]-1-benzofuran-5-carboxamide;

N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]-1-benzofuran-6-carboxamide;

N-[(2S,3R)-2-methyl-1-azabicyclo[2.2.2]oct-3-yl]-1-benzofuran-5-carboxamide;

N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]-3-bromo-1-benzofuran-5-carboxamide;

N-[(1S,2R,4R)-7-azabicyclo[2.2.1]hept-2-yl]-3-bromo-1-benzofuran-5-carboxamide;

N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]-3-methyl-1-benzofuran-5-carboxamide;

N-[(1S,2R,4R)-7-azabicyclo[2.2.1]hept-2-yl]-3-methyl-1-benzofuran-5-carboxamide;

N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]-2-methyl-1-benzofuran-6-carboxamide;

N-[(3R,5R)-1-azabicyclo[3.2.1]oct-3-yl]-1-benzofuran-6-carboxamide;

N-[(2S,3R)-2-methyl-1-azabicyclo[2.2.2]oct-3-yl]-1-benzofuran-6-carboxamide;

N-[(3S)-1-azabicyclo[2.2.2]oct-3-yl]-1-benzofuran-5-carboxamide;

N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]-3-isopropyl-1-benzofuran-5-carboxamide;

N-[(1S,2R,4R)-7-azabicyclo[2.2.1]hept-2-yl]-3-isopropyl-1-benzofuran-5-carboxamide;

N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]-2-methyl-1-benzofuran-5-carboxamide;

N-[(1S,2R,4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-methyl-1-benzofuran-5-carboxamide;

N-[(3R,4S)-1-azabicyclo[2.2.1]hept-3-yl]-3-bromo-1-benzofuran-6-carboxamide;

N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]-3-ethynyl-1-benzofuran-5-carboxamide;

N-[(1S,2R,4R)-7-azabicyclo[2.2.1]hept-2-yl]-3-ethynyl-1-benzofuran-5-carboxamide;

N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]-3-prop-1-ynyl-1-benzofuran-5-carboxamide; and
N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]-3-cyano-1-benzofuran-5-carboxamide;

provided that the agonist is the free base or a pharmaceutically acceptable salt thereof.

48. The method of claim 41, wherein the compound is
N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]pyrazino[1,2-a]indole-3-carboxamide;
N-[(3R,4S)-1-azabicyclo[2.2.1]hept-3-yl]-1H-indole-6-carboxamide;
N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]-1-methyl-1H-indole-6-carboxamide;
N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]-1-benzothiophene-5-carboxamide;
N-[(3R,4S)-1-azabicyclo[2.2.1]hept-3-yl]-1-benzothiophene-5-carboxamide;
N-[(2S,3R)-2-methyl-1-azabicyclo[2.2.2]oct-3-yl]-1-benzothiophene-5-carboxamide;
N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]-1-benzothiophene-6-carboxamide; and
N-[(3R,4S)-1-azabicyclo[2.2.1]hept-3-yl]-1-benzothiophene-6-carboxamide;

provided that the agonist is the free base or a pharmaceutically acceptable salt thereof.

49. The method of claim 41, wherein the compound is
N-[(1S,2R,4R)-7-azabicyclo[2.2.1]hept-2-yl]thieno[2,3-c]pyridine-5-carboxamide;
N-[(1S,2R,4R)-7-azabicyclo[2.2.1]hept-2-yl]thieno[3,2-c]pyridine-6-carboxamide;
N-[(1S,2R,4R)-7-azabicyclo[2.2.1]hept-2-yl]thieno[3,4-c]pyridine-6-carboxamide;
N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]thieno[2,3-c]pyridine-5-carboxamide;
N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]thieno[3,2-c]pyridine-6-carboxamide;
N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]thieno[3,4-c]pyridine-6-carboxamide;
N-[(3R,4S)-1-azabicyclo[2.2.1]hept-3-yl]thieno[2,3-c]pyridine-5-carboxamide;
N-[(3R,4S)-1-azabicyclo[2.2.1]hept-3-yl]thieno[3,2-c]pyridine-6-carboxamide;
N-[(3R,5R)-1-azabicyclo[3.2.1]oct-3-yl]thieno[2,3-c]pyridine-5-carboxamide;
N-[(3R,5R)-1-azabicyclo[3.2.1]oct-3-yl]thieno[3,2-c]pyridine-6-carboxamide;
N-[(2S,3R)-2-methyl-1-azabicyclo[2.2.2]oct-3-yl]thieno[2,3-c]pyridine-5-carboxamide;
N-[(2S,3R)-2-methyl-1-azabicyclo[2.2.2]oct-3-yl]thieno[3,2-c]pyridine-6-carboxamide;
N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]-3-bromothieno[2,3-c]pyridine-5-carboxamide; and

N-[(1S,2R,4R)-7-azabicyclo[2.2.1]hept-2-yl]-3-bromothieno[2,3-c]pyridine-5-carboxamide;

provided that the agonist is the free base or a pharmaceutically acceptable salt thereof.

50. The method of claim 41, wherein the compound is

N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]-1,3-benzothiazole-6-carboxamide;

N-[(2S,3R)-2-methyl-1-azabicyclo[2.2.2]oct-3-yl]-1,3-benzothiazole-6-carboxamide;

N-[(3R,5R)-1-azabicyclo[3.2.1]oct-3-yl]-1,3-benzothiazole-6-carboxamide;

2-amino-N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]-1,3-benzothiazole-6-carboxamide;

N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]-1H-indazole-6-carboxamide;

N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl][1,3]dioxolo[4,5-c]pyridine-6-carboxamide; and

N-[(1S,2R,4R)-7-azabicyclo[2.2.1]hept-2-yl][1,3]dioxolo[4,5-c]pyridine-6-carboxamide;

provided that the agonist is the free base or a pharmaceutically acceptable salt thereof.

51. The method of claim 41, wherein the compound is

N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]pyrrolo[1,2-c]pyrimidine-3-carboxamide;

N-[(3R,5R)-1-azabicyclo[3.2.1]oct-3-yl]pyrrolo[1,2-c]pyrimidine-3-carboxamide;

N-[(1S,2R,4R)-7-azabicyclo[2.2.1]hept-2-yl]pyrrolo[1,2-c]pyrimidine-3-carboxamide;

N-[(3R,4S)-1-azabicyclo[2.2.1]hept-3-yl]pyrrolo[1,2-c]pyrimidine-3-carboxamide;

N-[(2S,3R)-2-methyl-1-azabicyclo[2.2.2]oct-3-yl]pyrrolo[1,2-c]pyrimidine-3-carboxamide;

N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]pyrrolo[1,2-a]pyrazine-3-carboxamide;

N-[(3R,5R)-1-azabicyclo[3.2.1]oct-3-yl]pyrrolo[1,2-a]pyrazine-3-carboxamide;

N-[(1S,2R,4R)-7-azabicyclo[2.2.1]hept-2-yl]pyrrolo[1,2-a]pyrazine-3-carboxamide;

N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]-6-bromopyrrolo[1,2-a]pyrazine-3-carboxamide;

N-[(2S,3R)-2-methyl-1-azabicyclo[2.2.2]oct-3-yl]pyrrolo[1,2-a]pyrazine-3-carboxamide;

N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]-6-ethynylpyrrolo[1,2-a]pyrazine-3-carboxamide;

N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]indolizine-6-carboxamide; and

N-[(2S,3R)-2-methyl-1-azabicyclo[2.2.2]oct-3-yl]indolizine-6-carboxamide;

provided that the agonist is the free base or a pharmaceutically acceptable salt thereof.